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ABSTRACT 
 
Progress of modern medicine relies on the discovery of new antibiotics. The increasing 
threat of antibiotic resistant bacteria, leading to an increase in morbidity and mortality of patients 
previously considered low risk, has highlighted the serious need for the expansion of antibiotic 
research and development. Historically, natural products have been the most successful source of 
antibiotics as they have complex and unique chemical structures and modes of action. Since most 
available antibiotics are originally a result of the secondary metabolism of bacteria and fungi, 
microorganisms from diverse environments capable of producing secondary metabolites have 
been and currently are being investigated for antibacterial production.  
Green microalgae are eukaryotic microorganisms that can be found in a very wide range of 
habitats, including extreme environments. These microorganisms are known to produce a series 
of commercially valuable compounds as a result of their secondary metabolism. The central aim 
of this thesis was to determine the potential of green microalgae as antibiotic producers collected 
(bioprospected) from water bodies near abandoned mine sites in Ontario, Canada. These water 
bodies exhibited a variety of chemical profiles, including high metal concentrations and low pH.  
Forty species of green microalgae were subsequently isolated and their extracts tested 
against various bacteria. The findings showed that 37.5% of these microalgae produced 
antibacterial compounds that seem to specifically inhibit the growth of Gram-positive bacteria, in 
particular the opportunistic pathogen Staphylococcus aureus. This was a higher success rate than 
any previous study on green microalgae. In addition, the evaluation of crude extracts of 
Chlamydomonas sp., the most common isolated species, demonstrated variation in antibacterial 
  
iv 
activity during cell growth. The highest antibacterial activity from this species was found in the 
exponential phase.  
Furthermore, green microalgal extracts exhibiting antibacterial activity also decreased the 
cell viability of malignant cells, particularly the rapidly dividing human ovarian carcinoma 
A2780 cells. However, the extracts did not decrease the cell viability of non-malignant cells. 
Taken together, the results of this thesis reveal that freshwater green microalgae from water 
bodies near abandoned mine sites are potential sources of antibacterial compounds against Gram-
positive bacteria and should be further investigated against rapidly dividing malignant cells.   
 
Keywords: abandoned mine sites, antibiotic, antibacterial activity, freshwater, green microalgae, 
viability, malignant cells. 
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CHAPTER 1: INTRODUCTION 
1.1 The “Golden Era” and the lack of new classes of antibiotics 
The discovery of antibiotics represents undoubtedly the major scientific achievement 
against deadly bacterial infections. Antibiotics have impacted medicine not only by curing 
infections and saving millions of lives, but also by preventing infections in chronic diseases, 
immunosuppression and extensive surgeries (Ventola 2015). The impact of antibiotic therapy on 
health care is reflected in changes in life expectancy (Wright 2014). For example, in Canada, life 
expectancy in the early 1920s for men was 58.8 years of age, whilst recently it is 78.3, and for 
women it was 60.6 and now 83 (Statistics Canada, 2012).  
The time between 1940 and 1960 is regarded as the “Golden Era” of antibiotics, as most 
available classes of antibiotic were discovered based on natural product screening (Fernandes 
2006). Soil actinomycetes and fungi were screened for antibacterial activity against test bacteria 
by measuring the zones of growth inhibition on agar plates (Lewis 2013). During this time, many 
new antibacterial drugs were discovered and became commercially available (Figure 1.1), 
generating a feeling of control over bacterial infections (Fernandes 2006). However, in the early 
1960s, bacterial resistance to antibiotics started to emerge and spread into hospital settings 
(Fernandes 2006).  
The search for new antibacterial compounds after the 1960’s based on natural product 
screening only resulted in rediscovery of known compounds (Silver 2011). As bacterial resistance 
to available drugs increased, other solutions had to be pursued (Lewis 2013). This included 
research on antibiotic analogs (Fernandes 2006) based on chemical modifications of previous 
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discovered antibiotics (Clardy et al. 2006). However, over two decades with these potent analogs, 
bacteria have evolved and circumvented their antibacterial activity, and, therefore, new classes of 
antibiotics are again needed (Coates et al. 2011).  
Figure 1.1- Timeline of most clinically used antibiotic investigation. Most major new classes of 
antibiotics were discovered and commercialized until 1961. Even though different technologies 
were applied no major classes of antibiotics were introduced from 1962 to 2000. Technologies 
used in antibiotic discovery are shown in red letters and new antibiotic classes in bold letters. The 
blue arrow shows the “innovation gap” (Adapted from Fernandes 2006, Fischbach & Walsh 
2009, Fernandes & Martens 2017). 
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The four decades that followed the “Golden Era” have been referred to as the “innovation 
gap”, as no major new classes of antibiotics were discovered (Fischbach & Walsh 2009, Figure 
1.1). This was certainly not due to a lack of technology, but in part as a result of the decrease in 
the commercial attractiveness of the antibiotic market after the “easier” antibiotic classes had been 
discovered (Stanton 2013). With the goal of maximizing profitability, pharmaceutical companies 
redirected their resources to long-term use drugs that treat chronic diseases such as cancer, 
diabetes and cardiovascular diseases (Stanton 2013). 
In the 1980s, the companies still working on natural product screening switched efforts to 
the synthetic chemical route of small-molecule library screening due to the low probability of 
success and diminished productivity (Clardy et al. 2006). The focus was to identify bacterial 
proteins as potential targets for antibacterial compounds and screen for inhibitors (Fernandes 
2006). Even though promising enzyme inhibitors were obtained, issues regarding permeability, 
pharmacokinetics and toxicity have proven these inhibitors to be poor antibiotics (Silver 2011).  
This diminished “pipeline” of antibiotics has led to only a few classes of antibiotics 
commercialized since the 1970s, such as oxazolidinones and lipopeptides (Fernandes 2006). 
Although both these antibiotic classes were initially commercialized in the early 2000s, their 
discoveries date back to the 1970s and 1980s, respectively (Silver 2011). In order to discover new 
antibacterial compounds, a variety of technologies have been employed in the last two decades, 
including genomics, bioinformatics, combinatorial biology, cloning, crystallography, and high-
throughput methods (Silver 2011). Although promising leads have been discovered, the rate of 
success has been very low (Fernandes 2017). 
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These new technologies have not provided the hoped for “magic bullet” to generate much 
needed new antibiotics (Donadio et al. 2010), and the spread of multidrug resistant bacteria is 
continually increasing (Rokem 2007). According to the Centers for Disease Control and 
Prevention (CDC 2013), antibiotic resistant bacteria kill in United States at least 23,000 people 
each year as a direct result from the infections and contribute to two million illnesses. It is clear, 
therefore, that if the pressing need for new antibiotics is not met, a return to the pre-antibiotic like 
era is possible (Chopra 2013).  
However, considering that over two thirds of available antibiotics are the result of natural 
products or their derivatives (Fischbach & Walsh 2009), it is reasonable to assume that organisms 
are still excellent potential sources of these compounds. Furthermore, advanced technologies, 
including high-throughput screening, cultivation of unknown microorganisms, metabolomics and 
genome mining, are now available to make this investigation easier than in the past (Kealey et al. 
2017). Therefore, natural product screening should not be abandoned (Wright 2014).  
Even though many research chemists do not like to work with natural compounds due to 
their complexity, it is unquestionable that natural compounds can have advantages over synthetic 
ones. These include an ability to penetrate bacterial cells (Sheridan 2006). Other advantages of 
natural products may also include (Lam 2007):  
 unrivaled diversity promoting chemical complexity and biological activity; 
 use as a template in combinatorial chemistry for antibiotic analogs production; 
 possession of desirable pharmacokinetic properties.  
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As only a very small fraction of the world’s biodiversity has been explored (Sheridan 
2006), a small but growing number of studies have been focusing on the antibacterial potential of 
unexplored microorganisms, and they have shown that there is hope for antibiotic discovery. Ling 
et al. (2015) discovered teixobactin, a promising new class of antibiotic isolated from a 
previously unknown and uncultured bacterium from soil, which showed activity against 
methicillin-resistant Staphylococcus aureus. Maffioli et al. 2017 discovered a new broad-
spectrum antibiotic that inhibits RNA polymerase from extracts of soil actinobacteria. However, 
the antibiotics that are in late clinical development are still not enough, and more new active 
compounds need to be found (Fernandes 2017). 
In summary, there is a critical need for the continuous production of new antibiotics to 
combat the ability of pathogenic bacteria to evolve resistances. As new technologies are available 
to make the process easier, a potential solution is to go back to researching natural sources, 
particularly from previously unexplored microorganisms. 
1.2 Microalgae – an overview 
Algae are a heterogeneous group of thallophytes (plant-like organisms without 
differentiation into roots, stems and leaves). They conduct oxygen-evolving photosynthesis based 
upon chlorophyll a as their primary photosynthetic pigment, and have reproductive cells that lack 
a sterile covering of protecting cells (Lee 2008; Andersen 2013). These organisms are mostly 
autotrophic, generating complex organic molecules from inorganic sources (Bellinger & Sigee 
2010) and are associated with the evolution of life on Earth, since they remove CO2 and release 
O2 (Demirbas & Demirbas 2010). 
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The classification of algae is not as straightforward as it is for other organisms, since they 
do not represent a formal taxonomic group of organisms. They, instead, are an assemblage of 
phyla or divisions based on a combination of cellular characteristics (Sheath & Wehr 2003), 
including photosynthetic pigments and reserve products (Sheath & Wehr 2015). According to 
Lee (2008), the algae phyla include: Cyanophyta (cyanobacteria), Glaucophyta, Rhodophyta (red 
algae), Chlorophyta (green algae), Euglenophyta (euglenoids), Dinophyta (dinoflagellates), 
Cryptophyta and Heterokontophyta. However, there is no general agreement among phycologists 
about the exact number of algal phyla (Sheath & Wehr 2015). 
Algae are further classified into two subgroups, based on cell size and complexity: 
microalgae and macroalgae. Microalgae represent the majority of the algae and are microscopic 
unicellular organisms (with some colony-forming species), including eukaryotic and prokaryotic 
species. Macroalgae are eukaryotic multicellular organisms that resemble higher plants 
(Andersen 2013; Ge et al. 2016). 
Most algae are found in aquatic environments, with microalgae being the most frequently 
algae detected in water (Bellinger & Sigee 2010), where they function as the primary producers 
in the food chain (Lee 2008). However, microalgae can be also found in a variety of terrestrial 
environments, including extreme environments such as snowfields, desert soil, hot springs and 
arctic environments (Delwiche 2007). They are also found in environments where they are 
exposed to extremes of pH, salt concentration and radiation (Seckbach & Oren 2007). 
As a consequence of microalgal adaptation to extreme or stressed environments, these 
microorganisms exhibit metabolic changes that can interfere with the most vital functions of the 
cells, such as respiration, photosynthesis or cellular division, ultimately leading to cell survival 
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(Fogg 2001). Extreme environmental factors not only affect these basic cell functions, but also 
influence dynamic cell composition, as they intervene with the pattern, pathways and activities of 
cellular metabolism (Hu 2013). 
The effect of environmental factors on microalgal cells leads cells to increasing the 
production of certain compounds, which creates obvious biotechnological consequences (Hu 
2013). These compounds, usually the result of microalgal secondary metabolism, have made 
these microorganisms the target of investigation in different fields of biotechnology. Microalgae 
have been investigated as generators of green energy (Laamanen et al. 2016), as important 
sources in human and animal nutrition (Navarro et al. 2016a), as an incomparable food in 
aquaculture (Muller-Feuga 2013) and as sources of compounds of medical interest, such as with 
antiinflammatory, anticancer, antiviral, antifungal and antibacterial activities (Soontornchaiboon 
et al. 2012; Santoyo et al. 2012; Najdenski et al. 2013; Li et al. 2016). Although the number of 
studies on microalgal compounds for medical application has been increasing, microalgae are, 
however, still largely unexplored microorganisms in this field (Olaizola 2003).  
1. 3 Microalgae and secondary metabolism 
Secondary metabolism is the production of compounds that are not directly used by the 
cells for their growth or cell division (Carmichael 1992). Secondary metabolites are 
synonymously used with natural products (Maschek & Baker 2008) and include molecules that 
act as hormones, antibiotics, immunomodulatoring agents, pesticides, antitumor agents, growth 
promotors and toxins (Carmichael 1992; Demain 1998). While the primary metabolites are 
universal amongst microorganisms, the secondary metabolites are of restricted distribution, with 
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the biosynthetic capability tipically restricted to certain strains and conditions (Malik 1980; 
Shimizu 1996).  
The biosynthetic pathways of secondary metabolites are higly regulated systems (Skulberg 
2000). Under stress conditions, microorganisms reduce their growth rates and a pool of 
intermediates and end products of primary metabolism accumulate, and are used as precursors by 
specific pathway enzymes for the production of secondary metabolites (Malik 1980; Skulbert 
2000). The precursors, usually amino acids, appear to stimulate the production of secondary 
metabolites when in increased supply and/or by inducing the expression of biosynthetic enzymes 
(Demain 1998). These enzymes are usually coded by clustered genes on chromosomal DNA and 
therefore, gene regulation will have an important effect on secondary metabolite production 
(Demain 1998; Skulbert 2000). 
Microalgae have the ability to produce a series of secondary metabolites with diverse 
chemical structure and physiological functions (Skulberg 2000), which are not found in higher 
plants (Shimizu 1996). Despite microalgal potential, not many species have been investigated and 
their secondary metabolites identified (Shimizu 1996). Among microalgae investigated, 
cyanobacteria and dinoflagellates appear to be the most studied for the production of secondary 
metabolites  (Carmichael 1992; Shimizu 1996; Skulberg 2000). Green microalgae have been little 
investigated, which is most likely due to green macroalgae being known as the least prolific 
producers of natural products (Maschek & Baker 2008). However, studies investigating 
biological activities from extracts of green microalgae have shown an interesting ability of these 
microorganisms to produce unknown compounds that have antioxidant, anti-inflammatory, 
anticancer and antimicrobial activities (Gigova et al. 2011; Al-Wathnani et al. 2012; Garbayo et 
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al. 2012; Soontornchaiboon et al. 2012). Therefore, these microorganisms seem to have the 
potential to harbour compounds of medical interest that may lead to new needed drugs.  
1. 4 Microalgae and stress factors 
1.4.1 Stress 
Early knowledge on biological stress from unfavourable environments is based on the 
theories of Hans Selye, an endocrinologist from the Institute of Experimental Medicine and 
Surgery at McGill University. He studied the non-specific effect of stressors on humans. 
According to him, stress was the manifestation of a typical syndrome as a response to damage to 
the organism by non-specific agents, such as cold, surgical injury, excessive muscular exercise or 
intoxication with sub-lethal doses of drugs (Selye 1936).  
According to Fogg (2001), who investigated algae, stress is an inherited characteristic of 
the organism to respond to small or large stimulus from the environment that affects its biological 
processes. Davison & Pearson (1996) divided stress on algae into two different types: the 
limitation stress, a damage caused due to inadequate supply of resources, and the disruptive 
stress, where damage occurs because of adverse conditions (or the allocation of resources to 
prevent damage). Stress on microalgae has been further classified as physical, nutritional and 
biochemical (Fogg 2001). Examples of physical stress may include osmotic stress, desiccation 
and high/low temperatures. Nutritional stress includes the deficiency of essential nutrients and 
biochemical stress may include low pH and high concentration of metals (Fogg 2001). 
Furthermore, biotic stress factors, such as competition and predation, can also interfere with 
microalgal metabolism, leading to production of active compounds (Leflaive & Ten-Hage 2007). 
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Studies have shown that microalgae from competitive habitats produce compounds of medical 
interest (Lustigman et al. 1988). 
The application of physical, nutritional and/or biochemical stresses on microalgae have 
shown to trigger the overproduction of commercially valuable constituents such as lipid for 
biodiesel production (Han et al. 2016) and carotenoids (Minhas et al. 2016) as food additive in 
the nutraceutical industry. Furthermore, microalgae collected from stressed environments, either 
natural or anthropogenic, that exhibit high temperature or low pH have shown the ability to 
produce compounds of medical interest (Al-Wathnani et al. 2012; Navarro et al. 2016b).  
Although different stress factors have shown to interfere with microalgae metabolism and 
activate the production of compounds of medical interest, this current study focuses particularly 
on abiotic stresses including low pH and high metal concentrations. 
1.4.2 Low pH  
Low pH in freshwater is usually associated with geothermal hot springs and mining 
activities (Fogg 2001). In mining, acid mine drainage (AMD) can create extremely low pH 
waters, usually a result of sulphides in rock strata becoming exposed to water and oxygen (Novis 
& Harding 2007). This phenomenon is usually the cause of low pH found in water bodies near 
mines (Novis & Harding 2007) and its main consequence is the disruption of the ecosystem with 
the elimination of sensitive species (Gray 1997). 
Any microalgae that are present in acid mine drainage have to thrive in a usually 
oligotrophic environment, where nutrients, particularly inorganic nitrogen and carbon, are scarce 
(Novis & Harding 2007). Most of the microorganisms present in such extreme environments are 
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prokaryotes, but eukaryotic microalgae have been also documented as being metabolic active in 
extremely acidic environments (Nancucheo & Johnson 2012). 
In order to survive in acidic pH environments, microalgae have to confront high H
+ 
concentrations (Gross 2000). As many enzymes are highly dependent on pH, microalgae have to 
be able to maintain a neutral cytosolic pH (Gerloff-Elias et al. 2005). Therefore, these 
microorganisms are expected to demonstrate important adaptation changes, such as low 
conductance of the plasma membrane for H
+
, a high H
+ 
capacity and a high buffer capacity 
(Gimmler 2001). However, extreme pH conditions are known to exert an important influence on 
photosynthesis, growth and nutrient assimilation (Gerloff-Elias et al. 2005). As acidophilic 
microalgae present effective mechanisms to avoid the entrance of H
+
, important cations required 
for growth, such as K
+ 
and NH4
+
, are also prevented from entering the cells
 
(Gimmler 2001).  
The presence of freshwater green microalgae in areas of low pH have been observed 
(Stokes et al. 1973; Aguilera et al. 2007). The biotechnological potential of these 
microorganisms, thriving in low pH environments, has been investigated for their ability to store 
triacylglycerols for biodiesel production (Eibl et al. 2014; Hirooka et al. 2014; Ruiz-Dominguez 
et al. 2015). However, studies on the biological activities of microalgae from low pH 
environments are still scarce (Ruiz-Dominguez et al. 2015; Navarro et al. 2016b). Therefore, the 
ability of these microorganisms, from acidic environments, to produce compounds of medical 
interest, particularly with antibacterial properties, is still to be determined. 
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1.4.3 High metal concentration 
The ability of microalgae to survive in environments highly contaminated with heavy 
metals has been the focus of much investigation, in particular because of their bioremediation 
capacity (Monteiro & Castro 2012). Although the disposal of industrial wastes may expose 
microalgae to heavy metal contamination, water bodies affected by AMD are particularly prone 
to metal contamination, particularly where coal, pyritic sulphur, copper, zinc, silver and lead are 
mined (Gaur & Rai 2001; Gray 1997). Moreover, water bodies that have been contaminated with 
AMD have usually high concentrations of metals since the low pH is known to promote metal 
solubility in water (Gaur & Rai 2001; Novis & Harding 2007). 
Certain metals such as copper, iron, zinc and manganese, in small concentrations, are 
necessary for microalgal to perform important cell functions, such as photosynthesis, phosphorus 
acquisition and DNA transcription (Miazek et al. 2015). However, microalgae growing in the 
presence of high concentrations of metals have shown characteristics of toxicity including 
reduction in growth and photosynthesis, inhibition of enzymes activity, alteration in protein 
structure and membrane integrity (Monteiro & Castro 2012). 
Microalgae are known to be able to survive short periods of environmental stresses due to 
physiological acclimatisation through the modification of gene expression. However, when the 
extreme conditions exceed physiological limits, only mutations that confer resistance will enable 
microalgal adaptation (Garcia-Balboa et al. 2013). 
The ability of microalgae to survive in areas of high metal contamination has been 
associated to a series of mechanisms of resistance, including the increased production of 
  
13 
extracellular polymeric substances that prevent metals getting to the cytoplasm (Novis & Harding 
2007). The accumulation of metals inside the thylakoids (Novis & Harding 2007), the formation 
of metal complexes with excreted metabolites, activation of efflux pumps and elimination of a 
toxic metal through vaporization, by converting the metal into a volatile chemical species 
(Monteiro & Castro 2012) can all protect microalgae. 
Heavy metal toxicity affects the size, diversity, activity and genetic structure of 
microorganisms, leading to changes in morphology, metabolism and growth (Ayangbenro & 
Babalola 2017). Microalgae under metal stress have shown generation of reactive oxygen 
species, with a common example being peroxides and the consequent disruption of the plasma 
membrane by lipid peroxidation (Novis & Harding 2007). Moreover, microalgal cells may also 
respond to metal induced oxidative stress by producing chelating and antioxidant agents, and 
enzymes that quench reactive oxygen species (ROS) (Miazek et al. 2015). 
Interestingly, the evaluation of the Chlamydomonas eustigma genome, a green microalga 
adapted to environments with low pH and high metal concentrations, showed a series of genetic 
changes, including highly expressed genes of heat-shock proteins and plasma membrane H
+ 
-
ATPase, the loss of fermentation pathways responsible for acidifying the cytosol, energy shuttle 
and buffering system, as well as arsenic detoxification genes in order to adapt to these stressed 
environments (Hirooka et al. 2017). 
As microalgae adapt to environments with high concentrations of metals, metabolic 
adaptations will also occur (Nishikawa et al. 2003), which may lead to the production of 
compounds with biological functions (Garbayo et al. 2012). Although microalgae obtained from 
areas of high metal pollution have shown the ability to produce biologically active compounds 
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with antioxidant capacity (Garbayo et al. 2012), the ability of microalgae from these areas to 
produce active compounds with antibacterial activity has not been examined.  
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CHAPTER 2: THESIS HYPOTHESIS AND OBJECTIVES 
Microalgae constitute a vast untapped source of compounds with biological activities, 
therefore these microorganisms represent a potential resource for investigation into compounds 
with antibacterial activity. Previous studies investigating the production of antibacterial 
compounds by microalgae have mainly focused on cyanobacteria, with relatively little attention 
to green microalgae. Extracts from green microalgae have shown the ability to inhibit human 
pathogens; however, the strains evaluated are from non-stressed environments, including 
laboratory strains. Microalgae exposed to environmental stresses, on the other hand, are known to 
produce secondary metabolites: the primary source of existing microbial antibiotic compounds. 
However, the ability of green microalgae, thriving in hash environments, under a combination of 
stress factors to exhibit antibacterial activity against human pathogens has not been determined.  
2.1 HYPOTHESIS 
Freshwater green microalgae surviving in areas near abandoned mine sites, where high 
metal concentrations and low pH have been present for many decades, should have undergone 
adaptations that could lead to production of metabolites exhibiting antibacterial activity. This 
would make these organisms a potential new natural source of antibiotics. 
2.2 OBJECTIVES 
The main objective of this study was to evaluate freshwater green microalgae from areas 
near abandoned mine sites in Northern Ontario, Canada, for antibacterial activity. The specific 
objectives were to: 
  
16 
1) isolate green microalgae from water bodies near abandoned mine sites in Ontario; 
2) evaluate the in vitro susceptibility of Gram-positive and Gram-negative bacteria to methanolic 
extracts from these microalgae; 
3) determine the point during the microalgal growth cycle that the highest antibacterial activity of 
extracts occurs; 
4) assess the in vitro effect of extracts that exhibit antibacterial activity on mammalian cells 
viability. 
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3.1 ABSTRACT 
Bacterial resistance to antibiotics is an issue receiving significant attention and highlights the 
urgent need for new classes of antibiotics. This has led to exploration for natural compounds 
from relatively unexplored microorganisms including microalgae. These photosynthetic 
organisms are extremely diverse and ubiquitous and have been shown to produce compounds that 
exhibit antibacterial activity against human pathogens. Their ability to survive in a wide-range of 
environmental conditions and the possibility of culture condition manipulation for optimization 
of antibacterial compounds suggests that they have significant potential. However, only a few 
species have been so far investigated and very few metabolites characterized. This review 
provides an overview of this research and illustrates the opportunity for significantly more 
systematic investigation of these microorganisms. 
 
Keywords: Antibacterial activity, Bacteria, Metabolites, Natural compounds. 
 
 
 
 
 
 
 19 
3.2 INTRODUCTION 
An increase in bacterial resistance to existing antibiotics, which have been mostly obtained 
from bacteria, has encouraged the use of different technologies to find new efficient compounds. 
This has included the production of semi-synthetic and synthetic antibiotics (Fernandes 2006). 
However, increasing resistance to these compounds as well as the lack of new antibiotics 
highlight the need for continuous investigation to find new molecules and metabolic targets 
(Clardy et al. 2006). One successful approach that is being looked at again is the investigation of 
natural compounds, especially from untapped sources (Sheridan 2006). 
Natural compounds are known for a wide range of structural diversities and 
pharmacological activities (Harvey 2000) that are not seen in synthetic antibiotics (Fernandes 
2006). The recent exploration of alternative sources for these compounds has emphasized their 
potential for producing effective molecules against human pathogens  (Jang et al. 2013; King et 
al. 2014; Ling et al. 2015). 
This review focuses on investigation into the antibacterial activity of cyanobacteria and 
eukaryotic unicellular algae, microorganisms where photosynthesis is associated with chlorophyll 
a. Collectively, these microorganisms will be referred to as microalgae. 
 Photosynthetic microorganisms represent a potential source of antibiotic molecules, in 
particular secondary metabolites with chemical structures of low molecular weight less than 3000 
daltons (Hernandez-Carlos & Gamboa-Angulo 2011). These compounds, which are produced in a 
variety of concentrations, depending upon environmental conditions, have the potential to affect 
other organisms (Skulberg 2000; Leflaive & Ten-Hage 2007). 
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The number of reported assessments of microalgae as sources of antibacterial compounds is 
considerably lower compared to other organisms, such as bacteria and fungi (Clardy et al. 2006). 
However, the need for new antibiotics has stimulated an increase in work focused on extracting 
and testing natural compounds from alternative sources, including microalgae. Furthermore, 
advances in technologies for identification and purification of small amounts of bioactive 
compounds offer more precise and faster ways to screen alternative natural sources (Gil-Chavez 
et al. 2013). 
Screening programs have been established to find microalgal strains containing potentially 
useful secondary metabolites (Ordog et al. 2004; Plaza et al. 2010). Although the results look 
very promising, there are still no commercially available antibiotics from microalgae. This is 
likely due in part to the paucity of information regarding activity and toxicity in vivo (Borowitzka 
1995), as well as the challenges of controlled large-scale production (Skulberg 2000; Olaizola 
2003; Pulz & Gross 2004; Wijffels 2008; Skjånes et al. 2013).  
Metabolites from microalgae are extremely diverse, with some of them being successfully 
commercialized (Spolaore et al. 2006; Borowitzka 2013). These microorganisms produce a wide 
range of chemical classes including alkaloids, indoles, macrolides, peptides, terpenes, 
acetogenins, phenols, fatty acids and volatile halogenated hydrocarbons (Amaro et al. 2011). A 
few of these have been associated with growth inhibition of pathogenic microorganisms 
(Hernandez-Carlos & Gamboa-Angulo 2011). 
Microalgae offer interesting advantages as potential producers of antibiotics: they are 
extremely evolutionary and phylogenetically diverse (Borowitzka 1995); they can grow in 
bioreactors on a large-scale (Spolaore et al. 2006) and in inexpensive media (Pratt et al. 1944); 
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they can be stored by cryopreservation (Borowitzka 2013), and are able to produce a wide range 
of valuable organic compounds that can be manipulated by environmental changes (Andersen 
2013).  
 
Figure 3.1. Important studies between 1944 and 1979 that found antibacterial compounds from 
microalgae.  
3.2.1 Investigation of antibacterial activity of microalgae - an overview 
The use of microalgae as medicine occurred well before systematic scientific research 
began (Hoppe 1979). The first reported observation of  “toxic substances” secreted by microalgae 
was by Harder (1917) who worked with the cyanobacterium, Nostoc punctiforme (Kützing) 
Hariot (as Nostoc commune Vaucher ex Bornet & Flahault). Following on from this work there 
have been a few studies focused on agents excreted by algae cultured in colonies. The substances 
were described as being able to produce an auto-inhibitory effect as well as eliminate bacteria 
(Lefevre 1964).  
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Pratt et al. (1944) first isolated active compounds from microalgae. A mixture of fatty acids 
(chlorellin) from species of Chlorella showed in vitro inhibitory activity against both Gram-
positive and Gram-negative bacteria. Interestingly, Pratt et al. (1951) described a practical 
application during World War II derived from the previous observations. According to them open 
sewage from the military installations, which had been heavily inoculated with Chlorella sp. was 
bacteriologically safe for discharge into local streams. It was noted that there was a reduction in 
the number of coliforms compared to areas where Chlorella sp. were not present (Pratt et al. 
1951). 
In the 1950s, systematic screening of algae for antibiotics began (Borowitzka 1995). 
However, over the subsequent decades the studies would focus mostly on macroalgae (seaweeds) 
(Mautner et al. 1953; Glombitza 1969; Reichelt & Borowitzka 1984). The use of these organisms 
as the main research targets was most likely due to their ready availability  (Duff et al. 1966), as 
well as already being a source of many bioproducts, including food, agar, alginates and iodine 
(Pratt et al. 1951).  
New observations on antibacterial activity of microalgae and potential antibacterial 
compounds slowly emerged through the 1950s to 1970s (Figure 3.1). The majority of these 
studies focused on the role of antibacterial substances in ecological interactions (Sieburth 1959; 
Burkholder et al. 1960; Jorgensen & Nielsen 1961; Duff et al. 1966; Bruce et al. 1967; 
Ramamurthy 1970; Berland et al. 1972). For example, Sieburth (1959) observed that a microalgal 
species from the Antarctic was able to release substances into the medium that reduced bacterial 
growth [Escherichia coli Migula (Castellani & Chalmers)], as well as modified the 
gastrointestinal flora of penguins that ingested the microalgae. In the following year, the same 
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researcher identified the microalga, a species of Phaeocystis, and isolated a volatile chemical (an 
acrylic acid) as being responsible for the antibacterial activity (Sieburth 1960).  
Although the compound described by Sieburth (1960) showed promise as a broad-spectrum 
antimicrobial, the minimal inhibitory concentration was relatively high compared to known 
antibiotics, and acrylic acid in vivo demonstrated potential toxicity (Sieburth 1961). Similarly, in 
1970, Ramamurthy evaluated the potential of the cyanobacterium Trichodesmium erythraeum 
Ehrenberg ex Gomont for antibacterial activity in the gastrointestinal contents of the sea gull 
Laurus brunicephalus Jerdon. Although no compounds were identified, it was observed that T. 
erythraeum obtained from the gull guts was able to inhibit in vitro growth of both marine and 
terrestrial bacteria (Ramamurthy 1970). 
Despite the knowledge that microalgae are able to produce antimicrobial substances, in the 
1960s very little was known regarding the nature, formation and action of the antibacterial 
compounds produced (Jorgensen & Nielsen 1961). Burkholder et al. (1960) observed that cell 
extracts of the dinoflagellate, Gonyaulax tamarensis Lebour [as Alexandrium tamarense (Lebour) 
Balech], were able to inhibit growth of Staphylococcus aureus Rosenbach but also promote the 
growth of a marine bacterium. Similarly, culture filtrates of Chlorella vulgaris Beijerinck showed 
ability to inhibit but also accelerate growth of S. aureus (Jorgensen & Nielsen 1961). Although 
light seemed to play a role, factors and conditions influencing these behaviors were unknown.  
During the 1960s and 1970s bacterial resistance to existing antibiotics became an important 
issue, adding urgency to the search for new compounds and new metabolic targets (Fernandes 
2006). Antibiotic analogs (e.g. penicillin and cephalosporin derivatives) started to be synthesized 
in an effort to combat bacterial resistance (Brumfitt & Hamilton-Miller 1988). Duff et al. (1966) 
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were among the first to emphasize the need to investigate antibiotic metabolites from microalgae 
for therapeutic purposes. They assessed organic extracts from a wide panel of marine microalgae 
in vitro against marine and terrestrial bacterial strains. Although they saw selective action against 
bacterial strains, they also noticed the presence of bacterial resistance to crude extracts.  
In 1967, Bruce and collaborators reported isolation of two chlorophyll a derivatives from 
the previously investigated microalga, Isochrysis galbana Parke. When they tested these 
compounds against bacteria, they noticed similarities to previous results and suggested that the 
two chlorophyll a derivatives were actively responsible for antibiotic activity. 
Berland et al. (1972) isolated a peptide from the culture filtrate of Stichochrysis immobilis 
Pringsheim, which showed antibacterial activity against marine bacteria. Although their interest 
was to understand the importance of this activity in ecological interaction, the results showed the 
ability of the compound to inhibit bacteria from different origins. Similarly, in 1979, 
malyngolide, an antibiotic compound from the cyanobacterium Lyngbya majuscula Harvey ex 
Gomont was isolated and characterized after shown to be effective against Mycobacterium 
smegmatis (Trevisan) Lehmann & Neumann and Streptococcus pyogenes Rosenbach (Cardllina 
II et al. 1979). 
In the 1980s, four decades after Pratt et al. (1944) isolated the first antimicrobial compound 
from microalgae, screening of photosynthetic microorganisms for antibiotics became more 
common. Cyanobacteria have been the major investigated photosynthetic microorganisms (Bloor 
& England 1989; Jaki et al. 1999; Ghasemi et al. 2003; Ghasemi et al. 2004; Soltani et al. 2005; 
Volk & Furkert 2006; Parisi et al. 2009; Kumar et al. 2011).  
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3.2.2 Antibacterial activity of cyanobacteria 
Cyanobacteria are photoautotrophic organisms with a classic prokaryotic cell organization, 
but similarly to eukaryotes conduct photosynthesis and respiration in their active membrane 
system (Singh et al. 2011). They grow ubiquitously and produce in addition to toxins a wide 
range of bioactive metabolites (Bloor & England 1989), with potential application in 
biotechnology. These characteristics have made them focus of intense investigation in the last 
decade (Dahms et al. 2006; Wijffels et al. 2013).  
To date, only a few compounds have been extracted and commercialized, including 
nutraceuticals, cosmetic products, and other high value molecules (Spolaore et al. 2006; 
Borowitzka 2013). Some purified compounds have promising commercial applications as 
bioplastics, biofertilizers, antiviral, antifungal, anticancer and antibacterial drugs (Patterson et al. 
1994; Abed 2009; Leao et al. 2013).  
Lipophilic and hydrophilic extracts from cyanobacteria collected in different areas of the 
globe have been evaluated for their antibacterial activities in cell-based in vitro assays. In most of 
the studies bioassays have been performed using crude extracts, which have indicated that species 
collected from different habitats (e.g. soil, marine and freshwater environments) are rich sources 
of inhibitory substances against Gram-positive and Gram-negative bacteria (Volk & Furkert 
2006; Madhumathi et al. 2011; Prakash et al. 2011; Abdo et al. 2012; Kumar et al. 2012; 
Thummajitsakul et al. 2012; Yadav et al. 2012; Najdenski et al. 2013; Tiwari & Sharma 2013; 
Abazari et al. 2013; Mudimu et al. 2014).  
Although most studies on antibacterial activity of cyanobacteria follow standard 
methodologies, a few others lack important information such as crude extract concentration 
 26 
and/or a standardized bacterial concentration tested. Another omission includes the lack of 
solvent controls, which is essential as bacteria can be sensitive to the organic solvent used to 
recover the extract, therefore giving a potential false positive result (Fernandes 2003). Moreover, 
important missing data may include culture purity (axenic or non-axenic), which helps identify 
the species to be able to synthesize the effective compound (Borowitzka 1995). Similarly 
important is information regarding replicability, since it is not uncommon for natural sources to 
lose their ability to produce the compounds of interest (Wright 2014), as experienced by Ploutno 
& Carmeli (2000) working with Nostoc sp. (TAU-IL-220-1). 
Other important information to be determined when evaluating extracts for antibacterial 
activity is the concentration able to inhibit or kill bacteria. In particular, extracts showing 
minimum inhibitory concentrations (MIC) below the MIC standardized by the Clinical and 
Laboratory Standards Institute (CLSI) should be further investigated (Silver 2011). Furthermore, 
it is of great importance that evaluations of in vivo activity follow isolation of compounds, since 
it is unknown if the effect of such molecules in vivo will mimic the results found in vitro. 
A few studies have shown the in vitro effectiveness of purified and structurally identified 
compounds from cyanobacteria against bacteria. Among the bioactive compounds found is 
ambigol A from Fischerella ambigua (Kützing ex Bornet & Flahault) Gomont (EAWAG 108b), 
described as having potent activity against Bacillus subtilis (Ehrenberg) Cohn (Falch et al. 1993). 
Kawaguchipeptin B was extracted from Microcystis aeruginosa (Kützing) Kützing (NIES-88) 
and showed inhibition of S. aureus at a MIC of 1 μg/ml (Ishida et al. 1997). Noscomin is an 
extracellular diterpenoid produced by N. commune (EAWAG 122b) that showed inhibition of 
Bacillus cereus Frankland & Frankland (MIC 32 ppm), S. aureus (MIC 8 ppm) and E. coli (MIC 
128 ppm) (Jaki et al. 1999). A different diterpenoid was also extracted from N. commune 
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(EAWAG 122b) and exhibited potent antibacterial activity against Staphylococcus epidermidis 
(Winslow & Winslow) Evans (MIC 4 ppm) (Jaki et al. 2000).  
Other compounds extracted from cyanobacteria include coriolic acid, alpha-dimorphecolic 
acid and linoleic acid, from Oscillatoria redekei van Goor [as Pseudanabaena redeckei (van 
Goor) B.A.Whitton] (HUB 051), which inhibited the growth of S. aureus strains (Mundt et al. 
2003). Nostocyclyne, from Nostoc sp. (TAU IL-220-1), is a cyclophane that was able to inhibit 
the growth of S. aureus and B. subtilis (Ploutno & Carmeli 2000). Furthermore, pahayokolide A 
from Lyngbya sp. was able to inhibit both Bacillus megaterium de Bary and B. subtilis at a MIC 
of 5 μg/ml, but showed toxicity to zebrafish embryos (LC50 2.15 μM)  (Berry et al. 2004). 
Gamma-linolenic acid from Fischerella sp. inhibited S. aureus (ATCC 25923) (MIC 4 μg/ml) 
(Asthana et al. 2006) whilst ambiguine I isonitrile, extracted from Fischerella sp. (TAU IL-199-
3-1) inhibited B. subtilis (MIC 0.312 μg/ml) and Staphylococcus albus Welch (as S. epidermidis)  
(MIC 0.078 μg/ml) (Raveh & Carmeli 2007). Additionally, ambiguine I isonitrile inhibited S. 
aureus (MIC 8.9 μM), hapalindole G inhibited Mycobacterium tuberculosis (Zopf) Lehmann & 
Neumann (MIC 6.8 μM) and hapalindole H inhibited Mycobacterium smegmatis (Trevisan) 
Lehmann & Neumann (MIC 39.6 μM). All three compounds were extracted from F. ambigua 
(UTEX 1903) and showed low toxicity (IC50 > 128μM) against green monkey kidney cells (Mo 
et al. 2009a). Scytoscalarol was extracted from Scytonema sp. (UTEX 1163) and showed activity 
against S. aureus (MIC 2 μM), Bacillus anthracis Cohn (MIC 6 μM), and M. tuberculosis (MIC 
110 μM). Moreover, scytoscalarol exhibited low toxicity (IC50 135 μM) against green monkey 
kidney cells (Mo et al. 2009b). A new alkaloid (fischambiguine B) was extracted from F. 
ambigua  (UTEX 1903) and had inhibitory activity against M. tuberculosis (MIC 2 μM), S aureus 
(MIC 19.4 μM), and M. smegmatis (MIC 23.4 μM) (Mo et al. 2010). Furthermore, 
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fischambiguine B exhibited low toxicity (IC50 > 128μM) against green monkey kidney cells  (Mo 
et al. 2010). Table 3.1 illustrates some antibacterial compounds extracted from cyanobacteria.  
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Table 3.1. Antibacterial compounds extracted from cyanobacteria. 
Species Compound Chemical structure Reference 
Fischerella 
ambigua 
ambigol A 
 
Falch et al. 1993 
Microcystis 
aeruginosa 
kawaguchipeptin 
B 
 
Ishida et al. 1997 
Nostoc 
commune 
 
noscomin 
 
Jaki et al. 1999 
Nostoc 
commune 
diterpenoid 
 
Jaki et al. 2000 
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Table 3.1. (continued). 
Species Compound Chemical structure Reference 
Nostoc sp. nostocycline A 
 
Ploutno 
& 
Carmeli 
2000 
Lyngbya 
sp. 
pahayokolide 
A 
 
Berry et 
al. 2004 
Fischerella 
sp. 
-linolenic acid 
 
Asthana 
et al. 
2006 
Fischerella 
sp. 
F. ambigua 
ambiguine I 
isonitrile 
 
Raveh & 
Carmeli 
2007 
Mo et al. 
2009a 
 31 
Table 3.1. (continued). 
Species Compound Chemical structure Reference 
Scytonema 
sp. 
 
scytoscalarol 
 
Mo et al. 2009b 
Fischerella  
ambigua 
fischambiguine B 
 
Mo et al. 2010 
Many bioactive metabolites synthesized by cyanobacteria are a peptide, a macrolide, a 
combination of peptides and macrolides, or belong to the alkaloid class (Mandal & Rath 2015). 
Even though these classes of compounds are produced by other microorganisms, including the 
antibiotic-producing actinomycetes (Chaudhary et al. 2013), novel antibacterial metabolites are 
synthesized by cyanobacteria (Ploutno & Carmeli 2000; Mo et al. 2009a), which suggests these 
microorganisms are worthy of further investigation. 
3.2.3 Antibacterial activity of eukaryotic microalgae 
Eukaryotic microalgae are highly diverse organisms able to synthesize a series of bioactive 
compounds such as isoprenoids, polyketides, nonribosomal peptides, polyunsaturated fatty acids, 
and alkaloids, which makes them commercially interesting (Sasso et al. 2012). Further studies 
have identified fatty acids, terpenes, carbohydrates, glycolipids, lipoproteins, bromophenols and 
tannins that exhibit antibacterial activity against human pathogens (Stein & Borden 1984; 
Metting & Pyne 1986). However, little is known about these compounds. Remaining questions 
include under what conditions the compounds are produced and their synthesis enhanced, what 
bacterial species are most sensitive and how (bactericidal or bacteriostatic) and where they act on 
bacteria. 
It is known that microalgae accumulate cell-associated antibacterial substances (Cooper et 
al. 1983; Cannell et al. 1988). However, studies have shown different levels of antibacterial 
activity in microalgal culture filtrate, suggesting that microalgal cells excrete these substances, 
which may depend on the stage of growth and/or the species/strain evaluated (Pratt et al. 1944; 
Hansen 1973; Cooper et al. 1983; Kokou et al. 2012). 
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A limited number of studies have tested cell extracts for antibacterial activity using organic 
and inorganic solvents. Of the studies testing both lipophilic and hydrophilic extracts against 
bacteria, most have shown better results from lipophilic extracts obtained with solvents of 
different polarities (Ordog et al. 2004; Nair & Krushnika 2011; Seraspe et al. 2012). This 
suggests a lipophilic nature of the antibacterial compounds. However, in fewer studies, aqueous 
extracts showed broader antibacterial results, suggesting that the specific strain or harvesting time 
may play a role on the nature of the extracted compounds (Cooper et al. 1983; Nair & Krushnika 
2011). 
Crude extracts from different species of eukaryotic microalgae have shown effectiveness 
against both Gram-positive and Gram-negative bacteria, as well as M. tuberculosis (Prakash & 
Bhimba 2005; Desbois et al. 2009; Arun et al. 2012; Bai & Krishnakumar 2013; Danyal et al. 
2013). This could suggest their potential for producing compounds with broad-spectrum activity, 
which is highly desired for new antibiotics. On the other hand, some studies have shown a 
specific inhibitory activity against Gram-positive bacteria (Debro & Ward 1979; Cannel et al. 
1988), including methicillin-resistant S. aureus (MRSA) (Ohta et al. 1994; Ohta et al. 1995). 
These are interesting findings, considering the urgent need for effective antibiotics against Gram-
positive organisms such as methicillin-resistant staphylococci, penicillin- and erythromycin-
resistant pneumococci and vancomycin-resistant enterococci (Aksoy & Unal 2008). However, the 
numbers of studies focusing on isolation and identification of these metabolites is still quite low. 
This is likely to be due to greater interest in other microorganisms, in particular actinomycetes 
that are already known to produce antibiotics. Moreover, further investigations including toxicity, 
compound bioavailability, and in vivo effectiveness are needed. 
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Among the antibacterial compounds that have been identified from eukaryotic microalgae 
are acrylic acid (Sieburth 1960), fatty acids (Pratt et al. 1944; Findlay & Patil 1984; Ohta et al. 
1994; Desbois et al. 2008), and pigments such as carotenoids and chlorophylls and their 
derivatives (Bruce et al. 1967; Bhagavathy et al. 2011). The isolation and identification of 
compounds are extremely important to evaluate their novelty and effectiveness. However, it is 
likely that many compounds extracted from these organisms will be impractical as antibiotics for 
medical reasons, due to toxicity or inactivity in vivo (Borowitzka 1995). There may also be 
restrictions due to commercial reasons, such as the inability for chemical synthesis, as 
experienced by Pratt with chlorellin (Willis 2007). As a possible solution, Borowitzka (1995) 
suggested that these compounds could serve as lead molecules or find application in agriculture. 
Despite antibacterial products from microalgae being promising, one of the main challenges 
is likely to be the small concentration of compounds extracted (Ohta et al. 1994). This makes it 
difficult to produce a natural antibiotic from these microorganisms in large-scale. Nonetheless, if 
the compound has a great potential as antibiotic, the possibility of chemical synthesis through 
improved technologies may represent a feasible option (Borowitzka 2013). 
 
3.2.4 Factors and conditions affecting production of microalgal secondary metabolites 
exhibiting antibacterial activity  
Secondary metabolites differ from primary metabolites in that they are non-ubiquitous 
molecules that are usually not involved with energy production, structure or reproduction. They 
represent a wide range of biomolecules with important properties that include antibacterial 
activity (Demain 1981; Burja et al. 2001; Maschek & Baker 2008). 
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Variations in temperature, light, pH, salinity and nutrient availability have been extensively 
investigated for their impact on microalgal growth and their primary metabolism. This includes 
lipid (triacylglycerols) accumulation and other high-value biomolecule accretion, such as 
polyunsaturated fatty acids (Sang et al. 2012; Skjånes et al. 2013; Juneja et al. 2013; Breuer et al. 
2013). Secondary metabolites are similarly likely to be affected by environmental changes, as 
their production seems to be directly linked to primary metabolite pathways (Malik 1980; Burja 
et al. 2001).  
The production of secondary metabolites by microalgae can help these organisms survive in 
adverse conditions (Leflaive & Ten-Hage 2007). It seems plausible, therefore, to assume that 
strains growing in extreme environments or under induced metabolic stress will produce 
secondary metabolites with antibacterial activity.  
Lustigman et al. (1988) investigated extracts of Dunaliella spp. isolated from polluted 
versus clean waters. They noticed that a heat labile non-proteinous substance that inhibited E. 
coli was only produced by species from polluted water. It was, therefore, suggested that 
microalgae from highly competitive habitats are more likely to produce compounds with 
antibacterial activity.  
Al-Wathnani et al. (2012) evaluated antibacterial activity of microalgae that survived 
extreme temperatures in desert soils. According to their study, extracts of selected strains of 
cyanobacteria strongly inhibited bacterial growth, especially the Gram-negative Shigella sonnei 
(Levine) Weldin. Similarly, cell extracts of cyanobacteria collected from a hot spring in Iran were 
especially effective against Gram-positive bacteria, with large zones of inhibition obtained 
(Heidari et al. 2012).  
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Production of secondary metabolites appears to be species and even strain dependent 
(Leflaive & Ten-Hage 2007), and possibly also associated with specific environmental 
conditions. Therefore, careful evaluation of growth phase and conditions for each strain is 
necessary when assessing antibacterial production. Debro & Ward (1979) noticed that harvesting 
time was directly related to antibacterial activity in some freshwater microalgae. 
Cooper et al. (1983), who worked with diatoms, found a similar outcome. They observed 
that the cell growth phase at harvesting was a relevant factor when evaluating antibacterial 
activity, as higher activity was associated with the stationary phase. 
Limiting nutrients, light control and temperature were also shown by Trick et al. (1984) to 
influence the extracellular concentrations of a norcarotenoid (-diketone), an antibacterial 
compound released by the marine dinoflagellate, Prorocentrum minimum (Pavillard) J.Schiller 
[as Prorocentrum cordatum (Ostenfeld) J.D.Dodge]. 
Chetsumon et al. (1994) noticed that variations in CO2 concentration, light intensity, and 
inoculum concentration were also important factors for Scytonema sp. to produce antibacterial 
compounds in a photobioreactor. Ohta et al. (1995) showed the influence of nutrient availability 
on the antibacterial activity of Dunaliella primolecta Butcher (C-525) and Chlorococcum sp. 
(HS-101) extracts against MRSA. Extracts of D. primolecta cells growing in medium with 
modified concentrations of magnesium sulfate and calcium chloride were associated with 
enhanced antibiotic activity. Additionally, pH was also considered a key factor for controlling 
antibacterial activity of Synechococcus leopoliensis (Raciborski) Komárek [as Romeria 
leopoliensis (Raciborski) Koczwara] against S. aureus. A broad pH range (pH 5-10) was 
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appropriate for cell growth but not necessarily for the production of the antibacterial agent (pH 7-
9) (Noaman et al. 2004). 
3.2.5 Techniques and technologies for the identification of antibacterial compounds from 
microalgae 
Advances in technologies for detection, purification and identification of small amounts of 
molecules present in mixed extracts have increased opportunities for investigation of antibacterial 
compounds from natural products (Leeds et al. 2006).  The search for alternative unexplored 
sources of natural compounds has also created a new perspective for finding new lead molecules 
or new antibiotics (Harvey 2000).  
Most studies that tested antibacterial compounds from microalgae employed a biological 
screening approach, mostly in vitro antibacterial susceptibility testing, including agar diffusion 
and/or broth dilution techniques (Mo et al. 2009b; Seraspe et al. 2012). This approach allows 
selection of the most interesting strains and identification of important factors such as optimal 
growth conditions and selection of solvents used for extraction. 
In antibacterial drug discovery, once biological activity is detected, the following steps 
involve separation of complex mixtures, purification and structural elucidation of the single 
biologically active compound (Leeds 2006). Reports on the purification and identification of 
antibacterial compounds from microalgae are still scarce in the literature. On the other hand, the 
recent increase in antibiotic research, the potential of these organisms to produce secondary 
metabolites, and the availability of analytical technologies such as chromatography and 
spectroscopy should help stimulate further investigation of antibacterial compounds from 
microalgae.  
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Chromatography is a useful technology that separates compounds based on a system 
containing one mobile and one stationary phase. Before the advent of chromatography, the 
purification of natural compounds was done by extraction of large amounts of starting material, 
and crystallization of the pure substance in a few crystals (Ettre 2000). 
 When Pratt et al. (1944) discovered chlorellin from species of Chlorella they did not have 
the wide chromatographic separation techniques available today, as partition (liquid-liquid) and 
paper chromatography were just being introduced (Martin et al. 1941; Consden et al. 1944). At 
that time, column chromatography was the best choice for those dealing with separation of 
natural compounds. However, this technique was in its early stages and relied particularly on the 
skill of the researcher to prepare the columns (Ettre 2000). 
 Gas-liquid chromatography was introduced by James & Martin (1952), initially for 
separation of fatty acids and then later expanded to other organic compounds. In two decades this 
technique became the most important analytical technique for natural product mixtures (Ettre 
2000). Although it has an excellent separation capacity, its application is restricted to volatile 
samples (Marston & Hostettmann 2009), requiring extensive sample preparation to vaporize non-
volatile matrices (Seger et al. 2013).  
Porath & Flodin (1959) introduced the term “gel filtration” for fractionation of compounds 
using synthetic hydrophilic gel (dextran gel known as Sephadex) in column chromatography. In 
this technique, compounds were separated based on their molecular dimensions and the degree of 
cross-linkage of the gel (Porath & Flodin 1959). The technique was soon expanded to molecular 
size fractionation of hydrophobic macromolecules using polystyrene gel eluted with solvents, and 
its name changed to “gel permeation chromatography” (Moore 1964). These easy and 
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inexpensive techniques emerged and were named “size exclusion chromatography”, a branch of 
liquid chromatography (Ettre 2000). This has been used for initial fractionation of antibacterial 
compounds from microalgal extracts (Table 3.2). 
When the first antibacterial compound (acrylic acid) from a microalga was isolated and 
identified (Sieburth 1960) paper chromatography and x-ray crystallography were used, and the 
unknown compound was compared to a commercially available acrylic acid. 
The use of paper chromatography had the disadvantage of having slow migration rates, 
since only cellulose was available as the stationary phase matrix (Ettre 2000). 
Thin layer chromatography (TLC) was proved (Stahl 1958) to produce much quicker 
analysis of multiple samples, as a result of the separation being performed on a porous layer 
consisting of small particles and of the use of a variety of stationary phases, as well as 
semiquantitative analysis (Ettre 2000; Marston & Hostettmann 2009).  
Studies performing purification of antibacterial compounds from microalgae in 1970s and 
1980s used mostly gel chromatography and TLC (Table 3.2). TLC is a simple and fast technique 
that generates an image as a result. However, the technique presented problems with automation, 
quantitation and reproducibility (Marston & Hostettmann 2009), which were solved by high 
performance liquid chromatography (HPLC), the most used analytical tool (Ettre 2000). 
Following compound purification, structure elucidation is an essential step in drug 
discovery, allowing researchers to select new compounds and discard known ones, also called 
dereplication (Lang et al. 2008). Purified compounds from microalgae have been elucidated 
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(Table 3.2) by available spectroscopic techniques including mass spectrometry and nuclear 
magnetic resonance. 
Mass spectrometry (MS) is an analytical tool widely used to identify and quantify natural 
products. Its main advantages are speed, sensitivity, selectivity and versatility in analyzing solids, 
liquids and gases (Hocart 2010). Nuclear magnetic resonance (NMR) has been considered 
essential to establish molecular structures by providing structural information, atomic 
connectivity and stereochemistry that MS cannot (Mandal & Rath 2015). However, NMR works 
best if the substance analyzed is highly pure, due to the signal richness of its spectra (Seger 
2013). 
Advances in these techniques have made possible the complete structure elucidation of 
natural compounds by using small amounts of pure compounds (Leeds et al. 2006). Studies 
focusing on secondary metabolites from microalgae have used more recently available analytical 
tools and obtained interesting results. The use of matrix assisted laser desorption ionization time 
of flight (MALDI-TOF) MS allowed the identification of new secondary metabolites in extracts 
of cyanobacteria. Environmental samples were evaluated for novel compounds prior to culturing, 
with high sensitivity and low sample volume (Puddick & Prinsep 2008). Furthermore, real time 
mass spectrometry (DART-MS) was used to identify Nostoc sp. based on chemical finger 
printing analysis. The method was suggested as a means of providing rapid identification of the 
major components of a species (Singh & Verma 2012).   
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Table 3.2. Selected antibacterial compounds obtained from microalgae from 1960. 
Species Compound(s) Source Method (s) Reference 
Phaeocystis sp. acrylic acid cells 
paper C,
1 
X-ray crystallography 
Sieburth 
1960 
Stichochrysis imobilis 
peptide culture 
medium 
gel C, 
TLC
2 
Berland et 
al. 1972 
Lyngbya majuscula 
-lactone 
malyngolide 
cells 
gel C, 
X-ray crystallography 
Cardllina 
II et al. 
1979 
Navicula delognei
3 
ester cells gel C, TLC  Findlay & 
Patil 1984 
Fischerella ambigua  
 
ambigol A and B cells 
NPVLC,
4
 MPLC,
5
 R-P- 
HPLC,
6
EIMS,
7
 
HREIMS,
8
x-ray 
crystallography, NMR,
9
 
IR,
10
 UV
11 
Falch et al. 
1993 
Chlorococcum sp.  
Dunaliella primolecta 
 
-linolenic acid cells 
gel C, TLC, GC
12 
GC-MS,
13
 NMR 
Ohta et al. 
1995 
Microcystis 
aeruginosa  
kawaguchipepeptin 
B 
cells 
flash C,  
R-P-HPLC, MPLC, UV 
Ishida  et 
al. 1997 
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Table 3.2. Continued. 
Species Compound(s) Source Method (s) Reference 
Nostoc 
commune 
noscomin culture  
medium 
SPE,
14
 gel C, HPLC, TLC, 
IR 
2D
15
 NMR, ESIMS,
16
 UV 
Jaki et al. 1999 
Nostoc sp. 
nostocycline A cells gel C, HPLC, HREIMS, 
2D-NMR, IR 
Ploutno & 
Carmeli 2000 
Nostoc 
commune 
diterpenoid  
anthraquinone  
indane derivative 
cells gel C,  
R-P-C, 2D-NMR, EIMS 
 
Jaki et al. 2000 
Oscillatoria 
redekei 
fatty acids 
(coriolic acid and 
-dimorphecolic 
acid 
cells gel C, TLC, HPLC, NMR, 
MS, UV 
Mundt et al. 
2003 
Lyngbya sp. 
pahayokolide A cells 
gel C, SPE, HPLC,  
R-P-HPLC 
Berry et al. 
2004 
Table 3.2. Continued. 
Species Compound(s) Source Method (s) Reference 
Fischerella 
ambigua 
parsiguine culture 
medium 
TLC, gel C, 
NMR, IR 
Ghasemi et al. 
2004 
Fischerella sp. 
fatty acid 
(-linolenic acid) 
cells TLC, gel C, HPLC Asthana et al. 
2006 
Fischerella sp. 
alkaloids 
(ambiguine H   
and I isonitriles) 
cells flash C, gel C, R-P- 
HPLC, NMR, IR, UV  
HREIMS 
Raveh & Carmeli 
2007 
Scytonema sp. 
scytoscalarol 
 
cells Column C, MS 
2D-NMR,HRMS,
17
 
NMR 
Mo et al. 2009b 
Nostoc sp. 
CCC 537  
 
diterpenoid cells TLC, R-P-HPLC  
NMR, ESIMS, 
EIMS, IR, UV 
Asthana et al. 
2009 
1
 C, chromatography; 
2
 TLC, thin layer chromatography; 
3
 Navicula delognei f. elliptica Lobban 
[as Parlibellus delognei f. ellipticus (Lobban) E.J. Cox]; 
4
 NPVLC, normal-phase vacuum liquid 
chromatography; 
5
 MPLC, medium pressure liquid chromatography; 
6 
R-P-HPLC, reversed-phase 
high-performance liquid chromatography; 
7
 EIMS, electron-impact mass spectrometry; 
8
 
HREIMS, high-resolution electron-impact mass spectrometry; 
9
 NMR, nuclear magnetic 
resonance; 
10
 IR, infrared; 
11
 UV, ultraviolet–visible; 12 GC, gas-chromatography; 13 MS, mass 
spectrometry; 
14
 SPE, solid-phase extraction; 
15
 2D, two-dimensional; 
16
 ESIMS, electrospray 
ionization mass spectrometry; 
17
 HRMS, high-resolution mass spectrometry. 
The processing and analysis of extracts leading in many cases to a known compound is still 
a challenge for antibacterial research (Lang et al. 2008). This situation has been improved 
through the use of hyphenated techniques (Wolfender et al. 2006). Hyphenated techniques 
combine both chromatographic and spectral methods exploiting the separation of compounds by 
chromatography and identification by spectroscopy (Patel et al. 2010). This combination allows 
researchers to determine the potential novelty of a compound based on both mass and elution 
time before large-scale purification and characterization (Puddick & Prinsep 2008). Some 
examples of widely used hyphenated techniques include gas chromatography-mass spectrometry 
(GC-MS), liquid chromatography-mass spectrometry (LC-MS), LC-NMR, and LC-NMR-MS. 
The coupling of HPLC with MS (LC-MS) is very efficient in terms of detection, 
quantification and identification of a wide range of natural products. The direct coupling of 
HPLC with NMR can provide full structure elucidation and stereochemical information 
(Wolfender et al. 2010). Furthermore, the coupling of LC with MS or NMR enables separation of 
molecules preceding analysis, resulting in improved signal intensity. The combination of 
ultrahigh pressure liquid chromatography with time-of-flight MS detectors has shown to be very 
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effective for identification of new compounds and dereplication of natural product extracts 
(Mandal & Rath 2015). 
The availability of advanced analytical techniques should have an important impact on 
antibacterial discovery. The requirement of only small amounts of samples and the ability to 
separate compounds from complex matrices should simplify the investigation of natural sources 
including microalgae. Table 3.2 summarizes techniques and technologies that have been used to 
purify and identify compounds from microalgae. 
3.2.6 CONCLUSION 
The diversity and ubiquity of microalgae, together with their ability to produce secondary 
metabolites exhibiting antibacterial activity, could make them an important source of new 
antibiotics. Significant value may lie in their ability to survive and adapt to a wide range of 
environments along with the products synthesized when their environmental conditions are 
changed or stressed. A wide range of technologies are available to aid systematic identification 
and purification of these natural products, which combined with in vivo experiments, could lead 
to novel antibiotics. However, to date there has been relatively little research into these 
microorganisms and they mainly remain an “untapped” source. 
In summary: 
1. The need for new antibiotics means microalgae that produce secondary metabolites that inhibit 
Gram-positive and/or Gram-negative bacteria should be more extensively investigated. That in 
part could include reviewing existing libraries of known microalgae metabolites and testing 
promising candidates for antimicrobial activity. 
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2. Changes in environmental conditions have been associated with enhancement of antibacterial 
compounds production by microalgae. 
3. The ability of certain microalgal species to survive and adapt to extreme environmental 
conditions suggests that strains from these environments are particularly worthy of exploration 
for their potential to produce antibacterial compounds. 
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4.1 ABSTRACT 
Bacterial resistance to antibiotics necessitates the search for new sources of 
microorganisms able to produce these needed molecules, which are typically secondary 
metabolites produced as a protective mechanism. Microalgae can produce a wide-range of 
secondary metabolites as a response to environmental stress but have been the subject of little 
research as potential sources of antibiotics. As a step towards assessing their potential, we 
isolated 40 freshwater green microalgae from water bodies with a wide-range of metal 
concentrations and pH values that were near abandoned mine sites in northern Ontario, Canada. 
Microalgae from this region and these types of water bodies had not been previously investigated 
for antibacterial properties. Forty methanolic microalgal extracts were obtained, analyzed and 
tested against Gram-positive and Gram-negative bacteria, and 37.5% inhibited the human 
pathogen Staphylococcus aureus (Bacilli). This is a higher “hit-rate” than in previously published 
results, and furthermore, the minimum inhibitory concentrations against S. aureus were notably 
much lower than any other reported work. This is the first time such environments have been 
assessed, and whilst no clear association was observed between the metals and pH analyzed, and 
antibacterial activity, the findings do indicate that microalgae from anthropogenically stressed 
environments are a potential source of antibacterial compounds. That is, sites that are typically 
regarded as having no value and often very negatively perceived are potential sources of valuable 
bioactive compounds.  Therefore, future studies are necessary to determine what environmental 
thresholds are associated with the antibacterial activity of the freshwater green microalgae 
thriving in these environments. 
Keywords: Antibiotics, Antimicrobial, Metabolites, Pathogens, Stressed environments  
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4.2 INTRODUCTION 
The discovery of penicillin in the late 1920s and other antibiotics that followed represents 
the major scientific achievement against deadly bacterial infections (Fernandes 2006). Certain 
bacteria from soil and fungi have been successfully providing many antibacterial drugs (Lam 
2007). This was possibly due to these microorganisms producing secondary metabolites (Demain 
1981; Burja et al. 2001) that provide important mechanisms in ecological interactions (Leflaive 
& Ten-Hage 2007). However, the decrease in the effectiveness of existing antibiotics is 
necessitating research to look for unexplored natural sources (Jang et al. 2013; Stanton 2013; 
Ling et al. 2015).  
Microorganisms for potential investigation are the relatively little-explored microalgae 
(Mudimu et al. 2014; Patel et al. 2015). Due to their diversity and adaptability, microalgae are 
found in almost every ecosystem, including fresh and marine water, rocks and extreme 
environments such as desert soils, snow and hot springs (Lee 2008). Furthermore, microalgae 
have the ability to produce metabolites, which have garnered considerable interest as a potential 
source of biofuels (Wijffels et al. 2013; Eibl et al. 2014) and for bioactivities, including 
antioxidant, anticancer and to a lesser extent, antibacterial activity (Ghasemi et al. 2007; 
Bhagavathy et al. 2011; Gigova et al. 2011; Al-Wathnani et al. 2012; Goiris et al. 2012; Heidari 
et al. 2012).  
Eukaryotic freshwater microalgae are known mainly as a source of products such as 
proteins, pigments, lipids and polysaccharides (Borowitzka 2013; Koller et al. 2014). The limited 
studies that have looked at antibacterial activity put forward mainly fatty acids as the compounds 
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responsible; although terpenes, carbohydrates, glycoproteins, lipoproteins, bromophenols and 
tannins have been also suggested (Senhorinho et al. 2015).  
Microalgae can successfully adapt to environmental stresses (Garcia-Villada et al. 2002). 
Therefore, it is probable that unique metabolites with useful activities are produced as a result 
(Coates et al. 2013). For example, extracts from an acidophilic microalga produced antibacterial 
activity against human pathogens (Navarro et al. 2016b). As a consequence, wild strains 
collected from extreme environments, natural or anthropogenic, represent a potential target for 
antibacterial screening (Challouf et al. 2012). However, to date these microorganisms have been 
subject to little investigative work for antibacterial activity. 
In the Province of Ontario, Canada, there are over 250,000 lakes, and since the 19
th
 century 
the province has undergone extensive mine exploration. A historic lack of mine closure plans led 
to abandoned sites leaving behind contaminated water bodies (Cranstone 2002). As a result, 
stressed aquatic environments were created, especially from acid mine drainage, which has left 
high metal concentrations and low pH values, conditions that lead to ecosystem disruption and 
microorganism selectivity (Kwiatkowski & Roff 1976; Gray 1997). Green microalgae are, 
however, able to adapt to extreme environments as a result of spontaneous mutation (Garcia-
Balboa et al. 2013), or physiological acclimation through increased production of secondary 
metabolites (Osundeko et al. 2014). Therefore, eukaryotic microalgae that have adapted to 
extreme environments can be found in water bodies historically impacted by mining (Stokes et al. 
1973; Eibl et al. 2014).  
Mining-impacted water bodies are generally regarded as long-term liabilities, but we 
carried out the first study to determine the antibacterial potential of freshwater microalgae found 
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in these environments. We hypothesized that these green microalgae underwent significant 
adaptation, with cells producing protective secondary metabolites, including those with 
antibacterial activity. To this end, we investigated the diverse phylum Chlorophyta (green algae) 
in water bodies located within 5 km of abandoned mine sites in northern Ontario, Canada.  
4.3 MATERIALS AND METHODS 
4.3.1 Sampling 
Collection sites near abandoned mines (Figure 4.1) were chosen based on the global 
positioning system coordinates provided by the Ontario Ministry of Natural Resources in the 
Abandoned Mines Information System (AMIS 2014). These sites were accessed by a Bell 206 
helicopter, between May and September of 2014. Water samples (250 ml) were collected from 
the water surface in 300 ml sterile Nalgene bottles and transported to the laboratory on ice. Upon 
return to the laboratory, 50 ml of each sample was sent for water chemistry analysis at Glencore 
Process Support (formerly Xstrata Process Support), Falconbridge, Ontario, Canada, where 
samples were analyzed for the presence of metals through ion chromatography (IC) and pH. In 
the laboratory, Bristol's modified medium (Bold 1949) was added to the remaining 200 ml water 
samples to increase nutrients by 10%. They were then left to grow at room temperature (21 ± 
2C) for two months under 12:12 hour light:dark cycle using fluorescent light (70-80 μmol 
photon m
-2
s
-1
).   
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Figure 4.1. Collection sites near abandoned mines chosen based on the Abandoned Mines 
Information System (AMIS 2014). Water samples (250 ml) were collected from the water 
surface, between May and September. Abandoned mine sites in Ontario (), water samples in 
which microalgae were isolated: with antibacterial activity () and without antibacterial activity 
(✖). The map extends from latitudes 45-50°N, and longitudes78-84°W. 
4.3.2 Isolation of green microalgae 
One hundred water samples were randomly selected for green microalgal isolation. Once 
the algae visually flourished in the bottles, 20 L from the bottom was transferred with a Pasteur 
pipette and streaked onto Bold’s basal medium (BBM; Bold 1949) agar plates and left under 24 
hours light (70-80 μmol photon m-2s-1) for 3-4 weeks until green microalgal colonies were seen. 
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BBM with bacteriological agar (1.5% w/v) was prepared and 40 mL poured into Petri dishes. 
Serial dilutions and repeated streaking of green algal colonies were performed until monocultures 
were obtained. Microalgal monocultures were ensured by regular observation using an inverted 
EVOS XL light microscope (AMG, Bothell, Washington, USA). 
Morphological identification of green microalgae at generic level was performed using an 
inverted light microscope (AMG EVOS XL light microscope) as per Shubert (2003) and 
Bellinger & Sigee (2010). Cultures were tested for bacterial and fungal contamination by 
streaking each microalga onto nutrient agar (EMD Chemicals Inc., Darmstadt, Germany) and 
Sabouraud 2% glucose agar (Fluka Analytical, Seelze, Germany), and incubating over 7 days at 
37C and 25C, respectively. Only axenic cultures were subsequently screened for antibacterial 
activity. 
4.3.3 Extract preparation 
For intracellular extract preparation, each strain was cultivated on two plates of BBM agar 
for 28 days, at 21 ± 2C, under a 12:12 hour light:dark cycle (70-80 μmol photon m-2s-1). Two 
agar plates were used per strain to ensure sufficient biomass for screening. Extraction procedures 
were according to Al-Wathnani et al. (2012) with modifications. Cells were harvested, washed 
twice in sterile water, centrifuged (2000 g for 15 min), frozen at -80C and freeze-dried. Dry 
biomass (108–297 mg) was weighed, and 0.08 ml of methanol mg-1 dry biomass was added. The 
tubes were agitated for 24 hr at room temperature. The procedure was repeated three times and 
the extracts combined. The tubes were then placed under vacuum to evaporate the solvent, after 
which the extracts were weighed (10–49 mg) and 100% dimethyl sulfoxide (DMSO) added to 
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create a final concentration of 50 mg ml
-1
. For each strain, three extracts were prepared for 
screening. 
4.3.4 Preliminary screening for antibacterial activity 
Microalgal extracts were tested against Gram-positive Staphylococcus aureus ATCC 25923 
and Bacillus subtilis ATCC 6051 and Gram-negative Proteus vulgaris ATCC 33420 and 
Escherichia coli ATCC 11303, using the agar diffusion method (Balouiri et al. 2016) with 
modifications. The bacteria were cultivated separately in nutrient broth (EMD Chemicals Inc.) 
for 24 h. Bacterial cultures were then adjusted to 0.5 McFarland turbidity standard and seeded 
onto Müller-Hinton (Oxoid, Altrincham, England) agar plates with sterile swabs. To these plates, 
2 l of each algal extract was added on top of the streaked bacterium, in triplicate, and incubated 
at 37C for 18 hr. DMSO and methanol (2 l) were used as negative controls and antibiotic discs 
(10 g) of ampicillin and streptomycin (Becton, Dickinson and Company, Franklin Lakes, USA) 
used as positive controls. 
4.3.5 Minimum Inhibitory Concentration (MIC)  
For extracts exhibiting antibacterial activity against S. aureus, MIC was determined using a 
broth microdilution method (Andrews 2001). Fresh microalgal intracellular extracts were 
obtained from cells growing at 25°C in 300 ml of BBM in a shaker (INFORS HT Multitron 
Standard, Anjou, Quebec, Canada), continuously agitated at 125 rpm, under photosynthetic light 
(Sylvania Gro-Lux F15W / Gro T8, Padstow, New South Wales, Australia) using a 12:12 hour 
light:dark cycle (70-80 μmol photon m-2s-1). After 28 days, microalgae were harvested and 
extracted as previously described. Extracts were then filtered through a 0.2 m sterile filter 
(Fisher Scientific, Ottawa, Ontario, Canada) and dissolved in 100% DMSO to 50 mg ml
-1
 stock. 
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S. aureus ATCC 25923 growing on Mueller-Hinton (MH) agar for 18 hr was adjusted to 0.5 
McFarland turbidity standard in MH broth. Well plates were prepared with microalgal extracts 
(from 0.5 g ml -1to 1024 g ml -1) in a two-fold dilution in MH broth. Extracts in MH medium 
were inoculated into the sterile wells and the bacterium added to a final concentration of 
approximately 10
5
 colony-forming units ml
-1
 (10
5
 CFU ml
-1
). Plates were incubated at 37°C for 
18 h. Each plate contained six negative control wells (maximum 2% concentration of DMSO) in 
MH broth (100 l) and was inoculated with S. aureus (100 l), as well as six wells used as drug-
free (inoculum-only) controls (S. aureus in 200 l of MH broth). Additionally, each plate 
contained 12 sterility control wells with MH medium only. Ampicillin (from 0.5 g ml -1 to 1024 
g ml -1) was used as a positive control. The MIC was defined as the minimum concentration of 
extract or ampicillin that completely inhibited S. aureus growth. Extracts were tested in triplicate. 
Figure 4.2 shows a summary of the multi-step process of microalgal screening for antibacterial 
activity.  
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Figure 4.2. Isolation and screening procedure of freshwater green microalgae for antibacterial 
activity. 
 
4.3.6 Metabolite Profiling 
In order to determine the metabolic profile of the microalgal extracts showing promising 
antibacterial activity, they were analyzed using direct-injection liquid chromatography tandem 
mass spectrometry (DI-LC/MS/MS). Extracts at 50 mg ml
-1
 were prepared as previously 
described, frozen at -80C and sent to The Metabolomics Innovation Centre (TMIC), University 
of Alberta (Edmonton, Alberta, Canada) to be analyzed.  
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4.3.7 Statistical Analysis 
All values are reported as mean values ± standard error of the mean (SEM). Statistical 
analyses were performed using IBM SPSS Statistics for Macintosh, version 21 (IBM Corp., 
Armonk, New York USA). Metal concentrations, pH and distances from the mines between 
microalgae exhibiting and microalgae not exhibiting antibacterial activity were subjected to 
Mann-Whitney U test. Pearson r correlation coefficient tests were performed to determine 
association between metal concentrations and inhibition zones, between metabolite 
concentrations and inhibition zones as well as between each metabolite identified and pH. The 
point biserial correlation technique was used to determine association between metal 
concentrations, pH and distances from the abandoned mine sites and antibacterial activity 
(qualitative). Differences were considered statistically significant when P < 0.05. 
4.4 RESULTS 
One hundred water samples collected from water bodies within 5 km of abandoned mine 
sites in Ontario were selected for green microalgal isolation. From these, 62 samples harboured 
green microalgae able to grow on BBM agar, and 40 axenic strains were successfully isolated and 
kept on BBM agar. Each of these 40 strains came from a different water sample and was screened 
for antibacterial activity. 
Microalgae were identified at the generic level based on cellular morphology, and six 
different genera were identified and isolated: Chlamydomonas (42.5%), Coccomyxa (20%), 
Chlorella (17.5%), Scenedesmus (10%), Chlorococcum (7.5%) and Desmodesmus (2.5%) (Table 
4.1). 
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All strains were screened for antibacterial activity, and 15 (37.5%) showed activity against 
at least one of the bacterial species tested. From these positive extracts, 13 (86.7%) were from 
Chlamydomonas, one (6.7%) from Coccomyxa and one (6.7%) from Scenedesmus. Of the 
microalgal genera tested, 76.5% of the Chlamydomonas strains, 25% of Scenedesmus and 12.5% 
of Coccomyxa produced antibacterial activity (Table 4.1). 
All microalgal extracts that showed antibacterial activity inhibited S. aureus. From the 
positive extracts, 53.3% inhibited both Gram-positive bacteria, S. aureus and B. subtilis; and 
46.7% inhibited only S. aureus (Table 4.1). No extracts showed inhibition against the Gram-
negative bacteria E. coli or P. vulgaris. Extracts obtained from the standard strain 
Chlamydomonas reinhardtii P. A. Dangeard CPCC 11 inhibited only the Gram-positive 
bacterium, S. aureus, and did not inhibit any of the Gram-negative species tested. The extract 
obtained from a stock culture of Scenedesmus dimorphus (Turpin) Kützing UTEX 1237 showed 
no inhibition of the species tested. 
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Table 4.1. Antibacterial activity (inhibition zones and MICs) of green microalgal extracts. 
 
Extracts Microalgal 
Identification 
 
Antibacterial 
activity on 
agar plate   
S.a
1
         B.s
2
 
Inhibition zone (mm)
 
 
    
S.a
1
            B.s
2
 
MIC 
(g/ml) 
 
S.a
1 
M2   Coccomyxa sp. + + 5.0 ± 0  7.0 ± 0 512 
M4  Scenedesmus sp. + - 5.0 ± 0 - >1024 
M6   
 
 
 
Chlamydomonas sp. 
+ + 7.6 ± 0.33 6.0 ± 0 128 
M9 + - 11.6 ± 0.3 - 32 
M12 + + 15 ± 0 9.3 ± 0.33 16 
M13 + + 6.3 ± 0.33 3.3 ± 0.33 >1024 
M15 + + 8.3 ± 0.33 3.6 ± 0.33 256 
M16 + - 9.3 ± 0.33 - >1024 
M17 + - 5.0 ± 0 - 1024 
M18 + - 7.0 ± 0 - >1024 
M19 + + 14.3 ± 0.67 8.3 ± 0.33 32 
M20 + - 11.6 ± 0.6 5.6 ± 0.3 128 
M21 + + 8.6 ± 0.3 5 ± 0 >1024 
M23 + + 11.6 ± 0.6 6.3 ± 0.3 >1024 
M40  + - 10.3± 0.3 - 32 
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Table 4.1. Continued 
1 
S. aureus, 
2 
B. subtilis, NP not performed 
 
 
 
 
 
 
 
Extracts Microalgal 
Identification 
 
Antibacterial 
activity on 
agar plate   
S.a
1
         B.s
2
 
Inhibition zone (mm)
 
 
    
S.a
1
            B.s
2
 
MIC 
(g/ml) 
 
S.a
1 
CPCC11 C. reihardtii + - 8.3 ± 0.3 - >1024 
UTEX1237 S. dimorphus - - - - NP 
Ampicillin  + + 27 ± 0 23 ± 0 2 
Streptomycin  + + 18 ± 0 17 ± 0 NP 
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When extracts were screened on Mueller-Hinton agar, the diameter of the inhibition zone 
obtained (Figure 4.3) against S. aureus varied from 5 to 15 mm, with extracts M9, M12, M20, 
M19, M23 and M40 all showing inhibition zones above 10 mm. The inhibition zone of extracts 
inhibiting B. subtilis varied from 3 to 10 mm, with seven extracts showing an inhibition zone 
above 5 mm (Table 4.1). 
 
Figure 4.3. Green microalgal extracts tested against Staphylococcus aureus. 2 l of each algal 
extract was dispensed on the bacterial lawn, in triplicate, which was then incubated at 37C for 
18 hr. UTEX 1237 extract (top quadrant) exhibiting no bacterial inhibition; M19 extract on right 
quadrant, M20 extract on bottom quadrant, and M12 extract on left quadrant exhibiting bacterial 
inhibition. 
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Minimum inhibitory concentration (MIC) of the extracts was then determined for the 15 
showing inhibition of S. aureus. MIC values obtained varied from 16 to > 1024 g ml-1, with six 
(40%) inhibiting S. aureus growth at concentrations ≤128 g ml-1. From these, three extracts 
(M9, M19 and M40) inhibited S. aureus at 32 g ml-1and one (M12) at 16 g ml-1. However, 
extracts from the control, C. reinhardtii CPCC 11, inhibited S. aureus only at a concentration > 
1024 g ml-1 (Table 4.1).  
Chemical analyses were performed to determine the chemistry of the water samples, and 
concentrations of Fe, Ni, Cu, Zn, As, Cd and Pb were calculated, as well as pH (Table S1). Metal 
concentrations and pH of the water samples, as well as the distances from the abandoned mines, 
were compared for microalgae exhibiting and not exhibiting antibacterial activity, and no 
significant differences were observed (Table 4.2).  
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Table 4.2. Mean values of metal ions, pH, and sum of metal ions from water sample analysis and 
distance of water sample from abandoned mine sites.   
 
Results expressed as mean values ± standard error. Statistical analysis based on Mann-Whitney U 
test.  
 
Characteristic Positive microalgae for 
antibacterial activity (n =15)  
Negative microalgae for 
antibacterial activity (n =25) 
Fe (ppm) 2.2 ± 1.5 0.4 ± 0.2 
Ni (ppm) 0.07 ± 0.05  0.01 ± 0.01 
Cu (ppm) 0.06 ± 0.05 0.06 ± 0.03 
Zn (ppm)  3 ± 2.8  0.7 ± 0.6 
As (ppm) 0.001 ± 0.0001 0.009 ± 0.008 
Cd (ppm) 0.045 ± 0.04 0.004 ± 0.002  
Pb (ppm) 0.005 ± 0.003 0.07 ± 0.07 
pH 6.3 ± 0.4 6.8 ± 0.2  
Sum of metal concentration 
(ppm) 
5.4 1.3 
Distance from the abandoned 
mine sites (km) 
3.13 ± 0.44 2.9 ± 0.28 
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To investigate the relationships between the metals analyzed, pH, distance from the mines, 
and microalgal antibacterial activity, correlation tests were performed. The analyses showed no 
significant correlations (Table 4.3). 
To partially identify metabolites in the methanolic extracts exhibiting the most promising 
antibacterial activity against S. aureus, extracts were analyzed using DI-LC/MS/MS. A wide 
panel of metabolites was identified, including amino acids, glycerophospholipids, sphingolipids, 
acylcarnitines and biogenic amines (Table S2). 
To ascertain whether there was a relationship between the metabolites analyzed and the 
antibacterial activity obtained in this study, correlation tests were performed and the analysis 
showed no significance (Table 4.3). 
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Table 4.3. Correlation (r) between water sample measures and antibacterial activity, between 
distance from the mines and antibacterial activity, between metabolites and pH, and between 
metabolites and antibacterial activity.  
Measures r P 
Sum of metal concentration per sample vs antibacterial activity - 0.1 0.19 
pH vs antibacterial activity 0.2 0.2 
Distance from the mine sites vs antibacterial activity - 0.07 0.6 
Sum of metabolite concentrations per extract vs inhibition zones 0.24 0.6 
Sum of amino acid concentrations vs pH 0.25   0.5 
Sum of glycerophospholipids vs pH - 0.02 0.9 
Sum of sphingolipids vs pH 0.23 0.6 
Sum of acylcarnitines vs pH 0.18 0.7 
Sum of biogenic amines vs pH 0.34 0.4 
Sum of amino acids vs inhibition zones 0.19 0.67 
Sum of glycerophospholipids vs inhibition zones 0.56 0.19 
Sum of sphingolipids vs inhibition zones 0.52 0.2 
Sum of acylcarnitines vs sum of inhibition zones - 0.54 0.2 
Sum of biogenic amines vs sum of inhibition zones 0.04 0.9 
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4.5 DISCUSSION 
Microalgae under stressing conditions secrete substances that are not regularly produced 
(Fogg 2001), and these metabolites may function as anti-predator and anti-infection and they may 
also aid in communication (Coates et al. 2013). The current study is, to our knowledge, the first 
to verify that freshwater green microalgae from environments in proximity to abandoned mine 
sites can produce compounds that inhibit bacterial growth. The results showed not only that these 
microalgae exhibit antibacterial activity against Gram-positive bacteria, but also that these 
environments harbour a higher percentage of antibacterial producers (37.5%) than indicated by 
previous studies on microalgal screenings. For example, screening of freshwater algae (including 
green microalgae and blue-green algae) carried out by Cannell et al. (1988) found only 12% 
positive strains. Similar screenings of marine microalgae by Kellam & Walker (1989) and 
Mudimu et al. (2014), found that 21% and 29%, respectively, of algal extracts exhibited 
antibacterial activity. 
Another important finding was the promising antibacterial activity that certain microalgal 
extracts, M6, M9, M12, M19, M20 and M40, exhibited against S. aureus. The active 
concentrations were very low (16-128 g ml -1), notably lower than previously reported values 
(Table 4.1). Extracts of the green alga, Cosmarium sp., collected from a hot spring, showed S. 
aureus inhibition at 150 g ml -1 (Challouf et al. 2012), and extracts from Chlorococcum 
humicola (Nageli) Rabenhorst inhibited different bacterial species from 10,000 to 22,000 g ml -1 
(Bhagavathy et al. 2011). Considering that the crude extracts used in this work were a mixture of 
many compounds and that microorganisms usually produce active compounds at very low 
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concentrations (Borowitzka 1995), purification would be expected to significantly further 
decrease the MIC (Ordog et al. 2004).  
Our microalgal screening established that all methanolic extracts showing antibacterial 
activity inhibited Gram-positive bacteria; although no inhibition was seen against Gram-negative 
bacteria. Debro & Ward (1979) and Cannell et al. (1988) obtained similar results from freshwater 
algal extracts. Gram-negative bacteria are less susceptible to antibacterial compounds, because 
unlike Gram-positive bacteria, they have a protective outer membrane (Silhavy et al. 2010). On 
the other hand, Navarro et al. (2016b) observed antibacterial activity in extracts from the green 
microalga Coccomyxa onubensis strain SAG2510 (Fuentes et al 2016) mostly against Gram-
negative bacteria. According to their study, no promising antibacterial activity was detected from 
methanolic extracts. This difference in results may be explained by the different species/strains, 
since in our study no activity against Gram-negative bacteria was observed from any of the 
extracts analyzed. 
Of the Gram-positive bacteria we tested, S.aureus was more susceptible to the extracts than 
B. subtilis. Kellam & Walker (1989) obtained similar results while screening marine green 
microalgae. However, Cannell et al. (1988) found B. subtilis to be far more susceptible than S. 
aureus to freshwater algal extracts (including those from unicellular and filamentous eukaryotic 
algae, as well as cyanobacteria). The active compounds were not identified, and the bacterial 
mode of action was unknown. Hence the ability of these extracts to inhibit one Gram-positive 
species better than the other has not been explained. However, the results from the current study 
are very encouraging as S. aureus is an opportunistic species (Pantosti et al. 2007) that has 
exhibited a multi-drug resistant phenotype, including resistance to last-resort antibiotics (Wilson 
et al. 2003; Zhanel et al. 2008; Tarai et al. 2013; Cavalcante et al. 2014).  
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No significant correlations between antibacterial activity of microalgae and metals 
analyzed, pH or distance from the mine sites were obtained. However, based on the number of 
samples harbouring microalgae for antibacterial activity and the promising ability of these 
microalgae to inhibit S. aureus, environments near abandoned mine sites seem to have a higher 
than average potential for harbouring antibacterial producers, which warrants further 
investigation. 
It is possible that factors associated with abandoned mine sites, other than the isolated 
metals or pH, could influence the production of antibiotics by the green microalgae tested. One 
possible factor is the presence of other organisms, as studies have shown that microalgae produce 
antibacterial compounds when present in a competitive environment (Lustigman 1988; Kokou et 
al. 2012). Although fewer taxa are present in contaminated areas near abandoned mine sites than 
in unpolluted areas, the same phyla are found in both environments, with some organisms more 
prevalent in contaminated areas (Say & Whitton 1981).  
An interesting finding is that among the antibacterial microalgae obtained, Coccomyxa sp. 
(extract M2) and Chlamydomonas sp. (extract M23) came from water samples exhibiting 
extremely low pH (both 2.9; Table S1). Interestingly, both extracts demonstrated antibacterial 
activity against S. aureus. Navarro et al. (2016b) also observed that a strain of C. onubensis 
obtained from an acidic site (pH 2.5) exhibited antibacterial activity. These results suggest that 
green microalgae from extremely acidic water could be associated with the production of 
compounds with antibacterial activity and that future studies should target these extreme 
environments. Microalgae growing in highly acidic conditions demonstrate their adaptive nature, 
and significant changes in these organisms, such as increased internal buffer capacity, low 
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conductance of the plasma membrane and/or an increased ability to export H
+
 are not surprising 
(Gimmler 2001).  
Another factor that could influence microalgal antibacterial activity is the variation in 
temperature to which these microorganisms are exposed in fresh water in Canada. Yearly surface 
temperature of lakes in Ontario usually varies from 0C to approximately 24C (Schindler et al. 
1996), with most being ice-covered between December and March (Canadian Ice Service 
publications 2010). Variations in temperature affect permeability, metabolic regulation and rate 
of intracellular reactions in plants, with effects on growth and secondary metabolism 
(Ramakrishna & Ravishankar 2011). Also, variation in temperature has been shown to influence 
the ability of algae to accumulate secondary metabolites with antibacterial activity (Amade & 
Lemee 1998).  
Our analysis of metabolite concentration detected in the most active extracts of green 
microalgae showed no correlation with the antibacterial activity seen in this study. These results 
suggest that the metabolites that we identified do not have a direct association to the antibacterial 
activity in these microorganisms. Yet, it is possible that some of the metabolites identified are 
indirectly related to the production of antibacterial activity of freshwater green microalgae. Since 
the content of methanolic extracts from green microalgae exhibiting antibacterial activity is still 
largely unknown, the identification of metabolites present in these extracts warrants further study. 
The results of this study indicate that freshwater bodies near abandoned mine sites have the 
potential to harbour green microalgae that exhibit promising antibacterial activity against S. 
aureus. As these polluted water bodies are usually regarded as having no value, indeed often as 
problematic, considering their potential biochemical use could turn them from liabilities into 
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assets. However, since no clear association was found between antibacterial activity and metals 
analyzed or pH, future studies should explore this relationship to determine environmental 
thresholds that cause these microalgae to exhibit antibacterial activity.  
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5.1 ABSTRACT 
 Microalgae are being investigated for their ability to produce metabolites that have 
commercial value, including those with antibacterial activity. However, little is known about at 
what point during the microalgal growth phase they produce the maximum amount of metabolites 
exhibiting antibacterial activity. Furthermore, as research on antibacterial activity progresses, the 
effect of microalgal extracts on mammalian cells should be assessed.  
In this study, extracts from Chlamydomonas sp. that have previously shown activity against 
Staphylococcus aureus were investigated for antibacterial activity throughout their growth phase. 
Moreover, the effect of these microalgal extracts on the viability of non-malignant (MCF-10A 
and 184B5 cells) and malignant human cell lines (A2780 and MCF-7) was examined. The results 
demonstrated that Chlamydomonas sp. extracts showed higher antibacterial activity when 
harvested towards the end of the exponential phase. In addition, the extracts reduced cell viability 
of malignant cells at specific concentrations. The viability of non-malignant cells was not 
reduced by the extracts, but instead there appeared to be an increase in viability of these non-
malignant cell lines upon exposure to the extracts. 
 
Keywords: Antibiotics, Cancer, Eukaryotic microalgae, MTT, Viability 
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5.2 INTRODUCTION 
Microalgae have been investigated for their production of compounds with commercial 
interest, such as polysaccharides, proteins, vitamins, fatty acids and pigments (Cardozo et al 
2007; Sasso et al. 2012; Skjånes et al. 2012; Abd El Baky & El-Baroty 2013; Koller et al 2014; 
Michalak & Chojnacka, 2015). These compounds are either the result of microalgal primary 
metabolism, or the less understood secondary metabolism (Trick et al. 1984), and can provide 
important biological activities. These include antioxidant, antitumoral, antialgal, antiviral, and 
antifungal activities (Mudimu et al. 2014; Ruffell et al. 2016; Pina-Perez et al 2017). 
Investigations with microalgal extracts have revealed that certain organisms can produce 
metabolites that inhibit pathogenic bacteria (Navarro et al. 2016b; Senhorinho et al. 2018). 
Antimicrobial activity from natural sources is usually associated with the production of 
secondary metabolites (Leflaive & Ten-Hage 2007), those are produced as a result of the 
accumulation of intermediate and end products from the organism’s primary metabolism (Malik 
1980). Their production is thought to usually occur towards the end of the exponential phase or 
during the stationary phase of growth (Skulberg 2000; Leflaive & Ten-Hage 2007).  
For economic reasons if microalgae are to be screened for antibacterial activity, the 
harvesting time should be ideally at the earliest time of production in the growth curve and/or 
when the organisms produce the maximum amount of bioactive compounds. However, since the 
objective of screening is to quickly cover large numbers of organisms to select promising strains 
for further study, testing the antibacterial activity of each microalga over the entire growth curve 
would be laborious and unreasonable. Therefore, screenings are usually conducted after choosing 
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a harvesting day in either the exponential or stationary phase of growth (Najdenski et al. 2013; Li 
et al. 2016).  
Harvesting time has, however, been suggested as important to antibacterial activity of 
Scenedesmus strains (Aremu et al. 2014). Although the number of studies on antibacterial activity 
of microalgae has been increasing (Mudimu et al. 2014; Lauritano et al. 2016, Corona et al. 
2017; Senhorinho et al. 2018), little is known about the period in the growth curve at which 
microalgae start to produce antibacterial activity. Knowing when antibacterial activity is likely to 
occur would help researchers speed up the overall screening process by harvesting microalgae at 
the earliest point in the growth curve. 
In antibiotics discovery, once antibacterial activity is observed, determining the effect of 
the extract on mammalian cells is an important next step. That is, a promising new antibiotic 
needs to show low or no toxicity towards the mammalian cells (Chopra 2013). Microalgal 
extracts from eukaryotic and prokaryotic microalgae have been shown to decrease viability of 
both healthy and malignant mammalian cells (Bechelli et al. 2010; Hernandez et al 2016). 
Extracts from the green microalga Chloromonas sp. showed an anti-proliferative effect towards 
malignant cells, whilst no such effect was observed on non-malignant cells (Suh et al. 2017).  
Interestingly, studies have shown that microalgal extracts can contain compounds with 
growth inhibitory activity towards malignant cells and have been investigated as potential 
anticancer therapies (Hong & Luesch 2012). Microalgal extracts exhibiting antibacterial activity 
seem to also have an inhibitory effect on viability of malignant cells (Ordog et al. 2004). Since 
natural sources, such as microorganisms, can produce important compounds with anticancer 
activity, the effects of green microalgal extracts with promising antibacterial activity on 
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mammalian cell viability should be also evaluated. Once the effect on mammalian cell viability 
has been determined, it would be also interesting to determine if there is a difference between the 
response by malignant and non-malignant cells. 
To address these issues, we identified five Chlamydomonas sp., from screening freshwater 
green microalgae in water bodies near abandoned mine sites in Ontario, Canada, that showed 
promising antibacterial activity against Staphylococcus aureus. The purpose of this study was to 
determine the earliest period of growth in which freshwater green microalgal extracts 
demonstrate antibacterial activity against S. aureus, and to also provide an initial assessment as to 
in vitro impact of the extracts on viability of non-malignant and malignant human cell lines. 
5.3 MATERIALS AND METHODS 
5.3.1 Microalgal strains and growth conditions 
Five wild Chlamydomonas sp. (M6, M9, M12, M19, M40) collected from freshwater lakes 
near abandoned mine sites in Ontario, Canada, where microalgae survive at high metal levels and 
low pH, were used in this study (Senhorinho et al. 2018). The initial screening was on day 28 
(exponential phase) of microalgal growth, and the extracts from the five microalgae showed 
promising antibacterial activity against Gram-positive bacteria, particularly the human 
opportunistic pathogen Staphylococcus aureus ATCC 25923  (Senhorinho et al.  2018). Culture 
collection strains, Chlamydomonas reihardtii CPCC11 (Cr), which previously showed 
antibacterial activity on day 28 of growth, and Scenedesmus dimorphus UTEX 1237 (Sd), which 
did not show any antibacterial activity after growing for 28 days were also included in this work. 
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Isolates of green microalgae grown for 10 days (10 to 22 mg dried biomass) on Bold’s 
basal medium (BBM) agar plates (at 21±2C, under a 12:12 hour light:dark cycle, 70-80 μmol 
photon m
-2
s
-1
) were transferred to flasks containing 500 ml of liquid BBM. They were then 
grown for a further 49 days in an incubator (INFORS HT Multitron Standard, Anjou, Quebec, 
Canada), at 25°C, continuously agitated at 125 rpm, and under photosynthetic light (Sylvania 
Gro-Lux F15W / Gro T8, Padstow, New South Wales, Australia) using a 12:12 hour light:dark 
cycle (70-80 μmol photon m-2s-1). Axenic cultures were used in this study.  
5.3.2 Microalgal growth  
During growth, one milliliter samples were analyzed in triplicate every three days for 48 
days using a spectrophotometer (UV-1700 UVVIS, Shimadzu, Tokyo, Japan) at a wavelength of 
550 nm. 
5.3.3 Microalgal extract  
Each microalga was harvested every seven days over 49 days, washed twice with sterile 
water, centrifuged at 2000 xg for 15 min, frozen at -80C, freeze-dried and weighed. The 
resultant biomass was immediately used for preparation of extracts. Extracts were obtained 
following the methodology described by Al-Wathnani et al. (2012) with modifications. 
To the biomass obtained, 0.08 ml of methanol per mg of dry biomass was added and 
agitated for 24 hr at room temperature. The biomass was centrifuged at 2000 xg for 15 min and 
the supernatant removed. This procedure was repeated three times, the extracts combined and 
filtered through a 0.2 m sterile filter (Nalgene, Fisher Scientific, Ottawa, Ontario, Canada). 
Tubes with extracts were then placed under vacuum for solvent evaporation after which, extracts 
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were weighed and 100% dimethyl sulfoxide (DMSO) added to create a final concentration of 50 
mg/ml.  
Microalgal extracts to test on mammalian cells were prepared as described above. In order 
to compare the concentrations of extracts affecting mammalian cells with the concentrations 
affecting S. aureus cells, extracts were prepared with microalgal cells harvested on day 28, since 
the minimum inhibitory activity (MIC) of the extracts analyzed in this study was previously 
tested on day 28, exhibiting promising results against S. aureus ATCC 25923 (Senhorinho et al. 
2018).   
5.3.4 Antibacterial activity test 
Antibacterial activity tests were performed using the agar diffusion method according to 
Balouiri et al. 2016 with modifications. The extracts were tested against the Gram-positive strain 
Staphylococcus aureus (ATCC 25923). This bacterium was grown in nutrient broth (EMD 
Chemicals Inc., Darmstadt, Germany) for 24 hr, adjusted to 0.5 McFarland turbidity standard and 
seeded onto Müller-Hinton (Oxoid, England, UK) agar plates using sterile swabs. Two 
microliters of each extract was added on top of the bacterial lawn, in triplicate and incubated at 
37C for 18 hr. DMSO and methanol (2 L) were used as negative controls and antibiotic discs 
(10 g) of ampicillin and streptomycin (Becton, Dickinson and Company, Franklin Lakes, USA) 
used as positive controls. Experiments were performed as three biological replicates in triplicate. 
5.3.5 Mammalian cell culture conditions 
Two malignant cell lines, MCF-7 (breast carcinoma) and A2780 (human ovarian 
carcinoma); and two non-malignant cell lines, MCF-10A and 184B5 (non-tumorigenic mammary 
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epithelial lines) were used in this study. A2780 was obtained from the European Collection of 
Cell Culture and maintained in RPMI-1640 (Hyclone Laboratories, Logan, UT, USA) culture 
medium containing 10% fetal bovine serum (FBS). MCF-7 cells, from the American Tissue 
Culture Collection (ATCC), were maintained in MEM/EBSS (minimum essential medium with 
Earle’s salt solution: Gibco, Waltham, MA, USA) culture medium supplemented with 10% FBS 
and 10 g/ml of bovine insulin. MCF-10A (supplied by Dr. C. Lanner, Northern Ontario School 
of Medicine) was maintained in DMEM/F12 (Dulbecco’s modified eagle medium nutrient 
mixture F12: Gibco, Waltham, MA, USA) supplemented with 5% equine serum, 10 g/ml of 
insulin, 20 ng/ml of epidermal growth factor (EGF), 100 ng/ml of cholera enterotoxin and 0.5 
g/ml of hydrocortisone. Cell culture of 184B5 (ATCC CRL-8799) (supplied by Dr. C. Lanner, 
Northern Ontario School of Medicine) was maintained in MEGM (mammary epithelial cell 
growth medium: Clonetics, San Diego, CA, USA) with 1 ng/ml of cholera enterotoxin added. All 
cells were maintained in a humidified incubator at 37°

C with 5% CO2. No antibiotics were 
added to the cell cultures.  
5.3.6 Mammalian cell treatment and viability test 
Mammalian cell lines were grown in Corning T75 tissue culture flasks until cells reached 
confluence. Cells were then seeded (10
4 
cells/well) onto flat-bottomed 96 well plates for 24 h, 
and each well was treated with microalgal extract at various concentrations (5, 10, 25, 50, 100 
and 150 g/ml) for 24 h. Extracts for the cell treatments were obtained as previously described, 
after microalgal growth for 28 days. DMSO was present in the cultures at a maximum of 0.3%. 
Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay according to Khurana et al. (2014). Once the incubation time was 
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completed, MTT dye was added at 1/10th volume (5 mg/ml in PBS) (Sigma-Aldrich, Oakville, 
Ontario, Canada). Cells were then incubated at 37C with 5% CO2 for 4 hours, after which the 
medium was aspirated and 50 l of DMSO added. The plates were then incubated in the dark for 
15 min.  
The absorbance at 570 nm was measured on a plate reader (Bio Tek, PowerWave XS: 
Winooski, Vermont, USA). A cell control (untreated cells), DMSO control (0.01% - 0.3%) and 
blank (medium with no cells plus each extract at each concentration used plus MTT, and plus 
DMSO) were added in triplicate. Three independent experiments were carried out in triplicate.  
Optical densities of samples and vehicle were normalized to controls. The readings of the cell 
control, with untreated cells, were considered as 100% survival. The percentage survival of the 
mammalian cells was calculated according to van Meerloo et al. (2011) as follows: 
% of viable cells= (abssamples/vehicle – absblank/ abscontrol  –  absblank) X 100 
5.3.7 Statistical analysis 
All values are reported as mean values ± standard error of the mean (SEM). Statistical 
analyses were performed using IBM SPSS Statistics for Macintosh, version 21 (IBM Corp., 
Armonk, N.Y., USA). Repeated measures analysis of variance (ANOVA) with a Greenhouse-
Geisser correction followed by Bonferroni’s test was used to discriminate differences in 
antibacterial activity from Chlamydomonas sp. extracts between the different harvesting times. T-
tests were performed, to discriminate significant differences between microalgal extracts and 
controls when mammalian cells were treated. T tests with the Welch-Satterthwaite method were 
used when the factors failed the assumption of equal variance. Differences were considered 
statistically significant when P < 0.05.  
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5.4 RESULTS 
5.4.1 Microalgal growth. Microalgal biomass was first harvested on day seven, which was the 
beginning of the exponential phase, and last harvested on day 49, which was the early stationary 
phase (Figure 5.1). Microalgal growth was analyzed with spectrophotometry over the entire 
period (Figure 5.2). 
 
 
Figure 5.1. Microalgal biomasses harvested every seven days for 49 days. Microalgal cells in 
liquid BBM were harvested during cell growth, washed with water, centrifuged, frozen at -80C, 
freeze-dried and weighted.  The resultant biomasses are expressed as mean ± SEM (n = 3). Cr, 
extract from C. reinhardtii CPCC11; Sd, extract from S. dimorphus UTEX 1237. 
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Figure 5.2. Microalgal growth rate analyzed every three days for 48 days. Microalgal cells in 
liquid BBM were harvested during cell growth and analyzed through spectrophotometry at 550 
nm. Results are expressed as mean ± SEM (n = 3). Cr, extract from C. reinhardtii CPCC11; Sd, 
extract from S. dimorphus UTEX 123. 
5.4.2 Antibacterial activity. Extracts of all Chlamydomonas sp. inhibited S. aureus. On the other 
hand, extracts from the culture collection strains, C. reinhardtii and S. dimorphus, showed 
antibacterial activity until day 28 and 14, respectively. The controls, DMSO and methanol, did 
not show any inhibition of S. aureus growth (data not shown). However, a significant difference 
in antibacterial activity was observed among Chlamydomonas sp. harvesting times (P < 0.05). 
Extracts obtained from Chlamydomonas sp. showed significantly (P = 0.014) higher bacterial 
inhibition when harvested towards the end (day 35) of the exponential phase, and lower 
antibacterial activity at the early (day 49) stationary growth phase (Table 1). 
 
0.000
0.500
1.000
1.500
2.000
2.500
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
A
b
so
rb
an
ce
 O
D
 5
5
0
 n
m
  
 
Days 
M6
M9
M40
M19
Cr
M12
Sd
Table 5.1. Antibacterial activity of green microalgal extracts collected at different times during microalgal growth against S. aureus. 
Results are from measuring the zones of inhibition around extracts. 
*
Significant when zones of inhibition from extracts of 
Chlamydomonas sp. were analyzed. Different letters indicate significant difference based on repeated measures ANOVA (P < 0.05).
 
Controls: ampicillin (27 mm ± 0); streptomycin (18 mm ± 0). Results are expressed as mean values ± SEM (n = 3).
1 
Cr, extract from C. 
reinhardtii CPCC11; 
2 
Sd, extract from S. dimorphus UTEX 1237; 
3
MIC (the minimum concentration of extracts that completely 
inhibited S. aureus growth). 
Extracts Day 7 
*a
 
Zone in 
mm 
Day 14
*a
 
Zone in 
mm 
Day 21 
Zone in 
mm 
Day 28
*a
 
Zone in 
mm 
Day 35 
*b
 
Zone in 
mm 
Day 42 
Zone in 
mm 
Day 49 
*a 
Zone in 
mm 
MIC
3
 (g/ml) 
on day 28  
(Senhorinho et al. 2018) 
M6 11.5± 0.5 10.3± 0 0 11.6± 0.5 15.8± 0.1 13.6± 0.6 7.2± 0.1 128 
M9 13 ± 0.7 11.1± 0.1 9.8± 0.4 11.5± 1.2 15.6± 0.6 13.8± 0.3 5.7± 0.2 32 
M12 10.9± 0.7 10.8 ± 0.1 8 ± 0 10.8± 1.6 15.4± 0.3 15.7± 0.8 8.3± 0.2 16 
M19 12.7 ± 0.3 9.1 ± 0.1 9.6± 0.3 11.8± 1 15.8± 0.4 14.3± 0.3 6.5± 0.5 32 
M40 10.3± 1 10 ± 1.3 0 8.4± 1 13.3± 0.2 0 0 32 
Cr
1 
12.1± 1.7 11.4± 0.4 8.2± 0 7.2± 0.2 0 0 0 >1024 
Sd
2 
12.8 ± 1.2 9 ± 0 0 0 0 0 0 Not tested 
5.4.3 Effect of microalgal extracts on mammalian cell viability.  Non-malignant and malignant 
cells were incubated for 24 hours with each microalgal extract at various concentrations (5 – 150 
g/ml). The two non-malignant cell lines, MCF10A and 184B5, had no decrease in cell viability 
when compared to the control, but instead an increase in viability at some extract concentrations 
were observed, particularly for the cell line 184B5 (Figure 5.3). On the other hand, at some 
concentrations of extracts, the malignant cells, MCF-7 and A2780, showed a significant decrease 
in cell viability when compared to the control (untreated cells) (Figure 5.3). 
The 184B5 cell line showed a significant increase in cell viability when cells were treated 
with microalgal extracts at most concentrations tested, particularly extracts M40 and Sd (Figure 
5.3). The MCF10A cell line also exhibited increased viability when treated with some 
concentrations of microalgal extracts, in particular extracts from M6 and Cr (Figure 5.3). 
Moreover, MCF10A cells showed a significant increase in viability when treated with some 
concentrations of extracts from M9 and Sd (Figures 5.3C, 5.3D, 5.3E), with 150 g/ml of M19 
extract (Figure 5.3G) and 5 g/ml of M40 extract (Figure 5.3B).  
Of the two malignant cell lines, A2780 line was the most significantly affected by all 
microalgal extracts in terms of cell viability, but particularly by extracts from M9, M40 and M12 
(Figure 5.3). Extract from M9 exhibited the strongest effect on A2780 cell viability in a 
concentration-dependent manner, reducing 73% of viability when cells were treated with the 
highest concentration tested of 150 g/ml (Figure 5.3G). Extract from M40 exhibited 32% 
decrease in cell viability at the low concentration of 10 g/ml (Figure 5.3C) and 54% decrease in 
viability at the maximum concentration tested (Figure 5.3G). Moreover, extract from M12 
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reduced A2780 viability at 50 g/ml, 100 g/ml and 150 g/ml, with a reduction of 65% of 
viability at the highest concentration  (Figure 5.3G). 
 A less pronounced effect was seen on A2780 cell viability when cells were treated with 
extract M6, with a maximum of 31% reduction in cell viability at the highest concentration tested 
(Figure 5.3G). Furthermore, the extracts from the culture collections, Cr and Sd, had a significant 
impact on A2780 cell viability at all concentrations tested, with respective decreases of 49% and 
56%. Extract from M19 exhibited the least negative effect on A2780, with only significant 
decreases in cell viability at concentrations of 10 g/ml (24%, Figure 5.3C) and 25 g/ml (30%, 
Figure 5.3D). There was no significant difference in viability with the control at the higher 
concentrations tested (Figures 5.3E, 5.3F, 5.3G).  
MCF7 cells were negatively affected by extracts from M9 and M12 at only the highest 
concentrations tested (100 g/ml and 150 g/ml, Figures 5.3F, 5.3G). The cell viability was 
reduced by 59% and 39% when treated with 150 g/ml of extracts from M9 and M12, 
respectively (Figure 5.3G). MCF7 cells also exhibited a significant increase in cell viability when 
treated with 5 g/ml to 50 g/ml of extract from M40 (Figures 5.3B, 5.3C, 5.3D, 5.3E), 100 
g/ml and 150 g/ml of extract from M6 and 50 g/ml of extract from Cr. No effects were 
observed with MCF7 cell viability when the cells were treated with extracts from M19 and Sd 
(Figure 5.3).  
At the concentrations where microalgal extracts inhibited S. aureus growth (16 – 128 
g/ml) (Table 1), non-malignant mammalian cells showed no decrease in cell viability. Of the 
malignant cells tested, A2780 cells were negatively affected from 5 g/ml and MCF7 cells 
affected by concentrations above 100 g/ml.  
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The microalgal extract that exhibited the highest antibacterial effect (Table 1) against S. 
aureus, from M12, did not decrease non-malignant cells viability. However, a significant 
decrease in MCF7 and A2780 viability was observed when cells were treated with the highest 
concentrations of this extract (Figures 5.3E, 5.3F, 5.3G). 
The use of DMSO from 0.01% to 0.3% in the cell cultures did not significantly interfere 
with the cell viability of any of the cell lines tested in this study (Figure 5.3A). 
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Figure 5.3. Effect of microalgal extracts on non-malignant and malignant cells. One asterisk 
indicates significant differences to the control (control = cells only). Cr, extract from C. 
reinhardtii; Sd, extract from S. dimorphus. 
 
 
Figure 5.3A.Effect of DMSO on mammalian cell viability. Cells were treated with the same 
concentrations of DMSO as found in the treatments of mammalian cells. Cells were exposed to 
different concentrations of DMSO for 24 hours and MTT assay was performed (n= 3). 
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Figure 5.3B. Effect of 5 g/ml of microalgal extracts on mammalian cell viability. All 
mammalian cells were exposed to 5 g/ml of microalgal extracts and incubated for 24 hours. The 
cell viability was assessed by MTT assay (
*
P < 0.05, T-test). 
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Figure 5.3C. Effect of 10 g/ml of microalgal extracts on mammalian cell viability. All 
mammalian cells were exposed to 10 g/ml of microalgal extracts and incubated for 24 hours. 
The cell viability was assessed by MTT assay (
*
P < 0.05, T-test).
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Figure 5.3D. Effect of 25 g/ml of microalgal extracts on mammalian cell viability. All 
mammalian cells were exposed to 25 g/ml of microalgal extracts and incubated for 24 hours. 
The cell viability was assessed by MTT assay (
*
P < 0.05, T-test). 
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Figure 5.3E. Effect of 50 g/ml of microalgal extracts on mammalian cell viability. All 
mammalian cells were exposed to 50 g/ml of microalgal extracts and incubated for 24 hours. 
The cell viability was assessed by MTT assay (
*
P < 0.05, T-test).
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Figure 5.3F. Effect of 100 g/ml of microalgal extracts on mammalian cell viability. All 
mammalian cells were exposed to 100 g/ml of microalgal extracts and incubated for 24 hours.  
The cell viability was assessed by MTT assay (
*
P < 0.05, T-test). 
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Figure 5.3G. Effect of 150 g/ml of microalgal extracts on mammalian cell viability. All 
mammalian cells were exposed to 150 g/ml of microalgal extracts and incubated for 24 hours.  
MTT assay was performed (
*
P < 0.05, T-test).  
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DISCUSSION 
Microalgal extracts have been associated with biological activities, including antibacterial 
(Senhorinho et al. 2015; Pina-Perez et al. 2017). From previous work on microalgal extract 
screening, however, extracts are obtained from biomass harvested in either the exponential or 
stationary growth phase (Cooper et al. 1983; Ordog et al. 2004), which seems to encompass the 
times for production of antibacterial compounds (Leflaive & Ten-Hage 2007). Debro and Ward 
(1979) tested one harvesting day during the exponential growth phase and one at stationary 
phase, and observed that most green microalgae had higher antibacterial activity at exponential 
phase rather than at stationary phase.  
Antibacterial activity of freshwater green microalgae has not been previously 
systematically assessed over the growth curve and it is, therefore, not clear as to when is the 
earliest time to harvest microalgae when performing antibacterial activity screening. In order to 
determine if harvesting time plays an important role when screening for antibacterial activity, we 
harvested cells every seven days from early exponential to early stationary growth and tested the 
extracts against S. aureus. 
Our results demonstrated that all wild Chlamydomonas sp. extracts showed similar patterns 
of antibacterial activity, with significantly higher activity detected in the exponential phase (day 
35) compared to when cultures entered the stationary phase (day 49, Table 1). This represents an 
important finding, since to expedite the screening process it is key to know the earliest harvesting 
time.  
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The decrease of antibacterial activity at early stationary growth phase could indicate that 
the Chlamydomonas sp. produce less antibacterial compounds in this phase but also could 
suggest that these organisms start releasing the antibacterial compounds into the media. In this 
study, only intracellular extracts were evaluated. Noaman et al. (2004) observed the highest 
antibacterial activity from extracellular extracts of the cyanobacterium Synechococcus 
leopoliensis when cells were harvested during stationary phase of growth, indicating that the 
antibacterial compounds were released into the medium.  
The microalgal strains from culture collections showed different results from those of the 
wild microalgae. Extracts from C. reinhardtii CPCC11 only showed antibacterial activity until 
day 28 (exponential phase). Moreover, as indicated by the MIC results (Table 1), extracts from 
this strain showed weaker antibacterial activity against S. aureus than any of the extracts from the 
wild Chlamydomonas sp. tested. Similarly, extracts from S. dimorphus UTEX 1237 only showed 
antibacterial activity at the beginning of the exponential phase, which is until day 14. This 
observation is supported by our earlier work in which no antibacterial activity from S. dimorphus 
was detected when screened at day 28 (Senhorinho et al. 2018). Debro & Ward (1979) observed 
that extracts from a strain of C. reinhardtii showed the same antibacterial activity at the 
exponential and stationary phases, which was not seen in our study. However, studies have 
shown that antibacterial activity of green microalgae may vary, not only among species, but also 
among strains, which may explain these discrepancies (Ordog et al. 2004; Aremu et al. 2014; 
Senhorinho et al. 2015).  
Extracts M6 and M40 did not show any antibacterial activity on day 21, but was again 
detected on day 28. As microalgal metabolites are produced in very small amounts (Hernandez-
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Carlos & Gamboa-Angulo 2011), a decrease in antibacterial compounds that occur during the 
growth cycle could potentially lead to negative results in the assay.   
When extracts from a natural source demonstrate promising antibacterial activity, it is 
important to determine the effects on human cells. Even though extracts from a few microalgal 
species, including prokaryotic and eukaryotic, have been shown to decrease non-malignant and 
malignant cell viability (Bechelli et al. 2011), little is known about the effect of freshwater green 
microalgal extracts with antibacterial activity. As potential antibiotics, the compounds need to 
show potency against pathogenic organisms but low toxicity against mammalian cells (Olaizola 
2003).  
Therefore, in order to determine the effects of the microalgal extracts exhibiting 
antibacterial activity on mammalian cell viability, a viability test based on the reduction of 3-
(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) to a purple colour was 
performed. The microalgal extracts subsequently tested that showed promising activity against S. 
aureus resulted in no significant decrease in the observed cell viability of non-malignant 
mammalian cells, MCF10 and 184B5. This was observed even at the maximum extract 
concentration of 150 g/ml (Figure 5.3.7). However, extracts analyzed from the wild microalgae 
inhibited S. aureus growth at 16 g/ml to 128 g/ml (Table 1), which were much lower levels 
than obtained with a culture collection strain, suggesting these extracts are potent and worthy of 
further investigation.  
All the microalgal extracts tested decreased the viability of the malignant A2780 cell line at 
some concentration, with wild strains extracts M9, M12 and M40 exhibiting the most pronounced 
effects. Interestingly, extract M12 only had a negative effect on the cells at concentrations above 
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50 g/ml, whilst extracts M9 and M40 started affecting the cells at lower concentrations (Figs. 
3B, 3C). These results suggest that cytotoxicity, as is antibacterial activity, is extract dependent.  
Extracts from the culture collection strains, Sd and Cr, significantly decreased cell viability 
of the A2780 line at all concentrations tested. However, these extracts did not decrease cell 
viability of any other cell line. This suggests that the active compounds present in these extracts 
exhibit selectivity over the ovarian cancer cells, which are rapidly dividing cells. Moreover, since 
extracts from the culture collection strains, Sd and Cr, did not exhibit promising antibacterial 
activity, it is possible that antibacterial activity and antitumor activity are not directly related. 
The viability of MCF7 cells was significantly decreased by extracts M9 and M12, but only 
at the highest concentrations tested (Figures. 5.3.6, 5.3.7) and, interestingly, not by any other 
microalgal extract. Our results differ from the ones obtained by Ordog et al. (2004) who observed 
a decrease in MCF7 cell viability in cultures treated with all green microalgal extracts exhibiting 
antibacterial activity. However, different microalgal genera were used in our study, as well as 
specific concentrations of extracts, which may explain the discrepancies found with this study. 
 The wild microalgae tested in this study are originally from water bodies near abandoned 
mine sites, where high metal concentrations and low pH are commonly observed.  Extract M9 
was obtained from a Chlamydomonas sp. present in acidic water (pH 5.7) with high levels of iron 
while extract M12 came from a Chlamydomonas sp collected from an area with high levels of 
iron, nickel, copper and zinc (Senhorinho et al. 2018). Environmental stressors are known to 
contribute to microalgal adaptation (Leflaive & Ten-Hage 2007), which may lead these 
organisms to produce compounds that act on malignant cells. 
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 Interestingly, it was observed that microalgal extracts at most concentrations significantly 
increased the viability of non-malignant 184B5 cells, and certain concentrations of extracts from 
M6, Cr, M9, M40 and Sd also increased the viability of non-malignant MCF10A cells. In 
particular, extracts from M6 and Cr increased the viability of MCF10A cells at all the 
concentrations tested, except for Cr at 5 µg/ml. The MTT assay used to test viability is a 
quantitative colorimetric assay, where the tetrazolium salt is reduced to a water-insoluble 
formazan mainly by the succinate dehydrogenase enzyme of active mitochondria (Chakrabarti et 
al. 2000). Toxic compounds that damage the mitochondria of cells and reduce their viability, 
decrease the reduction of tetrazolium salt to formazan (Mueller 2004). Therefore, the absorption 
of the dissolved formazan usually correlates to the number of viable cells with active 
mitochondria or metabolism (Riss et al, 2016). The high MTT readings observed with the 184B5 
and MCF10A cells, would suggest that certain compounds found in microalgal extracts increase 
cell viability/proliferation of the non-malignant cells. However, it is also possible for some 
compounds to increase the mitochondrial enzymatic activity, thereby increasing MTT 
absorbance, without having an effect on cell number or cell viability (Pagliacci et al. 1993, 
Chakrabarti et al. 2000, Wang et al. 2010). Since a large number of compounds are likely present 
in the methanolic extracts of green microalgae (Annamalai & Nallamuthu 2014), it is possible 
that some of them increased mitochondrial metabolism, particularly of the 184B5 line. Therefore, 
further studies should look to identify and isolate the antibacterial compounds and their effects on 
human cells should be evaluated.   
MCF7 is a breast carcinoma cell line with slowly proliferating cells that express high levels 
of cytoplasmic estrogen receptors (Lee et al. 2015), whilst A2780 is an ovarian cancer cell line 
from an endometrioid adenocarcinoma tumor that rapidly proliferates. A2780 cells were 
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significantly more affected by the microalgal extracts than MCF7 cells (Fig 3). This suggests the 
presence of cytotoxic compounds in the microalgal extracts. Cytotoxic drug compounds work by 
preferentially killing rapidly proliferating tumor cells (Mitchison 2011) whilst slowly 
proliferating cells are less sensitive (Strese et al. 2013), which was seen in this study. 
Some variation was observed in the cell viability results when the replicates of the 
microalgal extracts were tested; particularly extract M12 at high concentrations (Figs. 3F, 3G). 
Microalgal extracts, as with other naturally sourced mixed biocompounds, have been shown to 
exhibit some variation in the concentrations produced during cultivation, and may even stop 
production of desired compounds (Ploutno & Carmeli 2000; Wright 2014), which is likely to 
explain the variation observed in this study. 
Overall, the results of the present study demonstrated, therefore, that harvesting time is very 
important when evaluating antibacterial activity of freshwater green microalgae. Intracellular 
extracts from wild strains of Chlamydomonas sp. exhibited higher antibacterial activity against S. 
aureus in the exponential growth phase, and have lower activity at stationary phase. Moreover, 
different microalgal genera and different strains demonstrate different patterns of antibacterial 
activity production during cell growth, as observed with the wild and the laboratory strain 
microalgae.  
Furthermore, methanolic extracts from freshwater green microalgae at the concentrations 
tested have the ability to decrease viability of malignant cells, particularly the rapidly 
proliferating cell line A2780, but not non-malignant cells MCF10A and 184B5. Therefore, these 
results suggest that extracts of freshwater green microalgae are worthy of further investigation as 
antibiotics that are not cytotoxic to human cells. Additionally, since the results indicate that green 
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microalgal extracts could harbour compounds that preferentially target malignant cells, more 
research is warranted needed to directly evaluate the compounds involved in this activity.   
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
The lack of new antibiotics represents a major concern for the progress of the modern 
medicine and the ability to directly save the lives of patients. The worldwide increase in bacterial 
resistance has created urgency for the discovery of novel antibiotic compounds and new bacterial 
targets to allow continuation of successful treatment of bacterial infections. Since most available 
antibiotics are restricted to actinomycetes and fungi from soil, which have have not provided any 
new compounds over the past decades (Wright 2012), alternative microbial sources could 
represent important targets for new antibiotics.  
The premise of this work was for the first time to analyze the potential of freshwater green 
microalgae found in water bodies near abandoned mine sites as antibiotic producers. Chemical 
analysis of these waters revealed that most of them were contaminated with metals and/or had a 
low pH (Table S1). The results of screening demonstrated that methanolic extracts obtained from 
certain microalgae isolated from these environments did exhibit antibacterial activity against 
Gram-positive bacteria, particularly S. aureus. Furthermore, compared to microalgae screened 
previously (Bhagavathy et al. 2011; Challouf et al. 2012), their extracts also exhibited better 
potential as antibacterial producers in terms of significantly lower minimum inhibitory 
concentrations (MICs). 
The antibacterial activity detected in green microalgal extracts was expected to correlate 
with the concentrations of heavy metals analysed and/or low pH detected by the water analysis. 
However, there was no statistical evidence that green microalgae, exhibiting promising 
antibacterial activity, have a direct association with environments with high concentrations of the 
metals analyzed or low pH. Nonetheless, based on the high occurrence rate of green microalgae 
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showing antibacterial activity, as well as low MIC values, there would appear that an association 
between these extreme environments and the antibacterial activity of microalgae is still likely to 
exist.  
Therefore, future studies should consider systematically investigating freshwater near 
abandoned mine sites for factors associated with the antibacterial activity. Factors such as 
ecological interaction (including with bacteria), which could be evaluated by molecular 
technologies such as polymerase chain reaction and/or DNA sequencing, could lead to a positive 
microbial association with antibacterial producer microalgae. Furthermore, the impact of very 
high seasonal temperature variations and extended periods of ice cover in Northern Ontario water 
bodies was not considered in this study. This could be associated with antibacterial activity of 
green microalgae, since a temperature correlation has been previously observed with macroalgae 
exhibiting antibacterial activity (Amade & Lemee 1998). Thus, studies on the effect of 
temperature variation on the antibacterial activity of microalgae could be an important avenue to 
be explored.  
An important part of this study was the evaluation of timing of biomass harvesting and 
antibacterial activity of green microalgal extracts. Microalgae from extreme environments have 
not been previously analysed during the growth curve for antibacterial activity. The results 
demonstrated that wild Chlamydomomonas sp. analyzed did indeed exhibit variation in 
antibacterial production during cell growth, with the maximum output towards the end of the 
exponential phase. This highlights that screening biomass harvested for antibacterial activity 
should not be performed at a random time during growth, as concentrations of active compounds 
may be too low to be detected. Moreover, this information is essential for further studies on 
identification and isolation of antibacterial compounds, as the cells should be harvested during 
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the highest peak of antibacterial activity, as the compounds are likely to be at higher 
concentrations. This finding is, therefore, important for further mass screening studies. 
In this study we also determined that microalgal extracts showing antibacterial activity did 
not decrease the cell viability of evaluated non-malignant cell lines. This result further suggests 
that these microorganisms are worthy of further investigation for antibiotic production, and that 
determination of the specific active antibacterial compound(s) should be pursued. Analysis of 
metabolites in the microalgal extracts, showing promising antibacterial activity, suggested that 
they are a rich source of amino acids, which are usually associated with the production of 
secondary metabolites (Demain 1998). Future experimental programs should include 
fractionation of the most promising extracts following by identification and isolation of the active 
compound(s).  
Furthermore, a very interesting finding of this study was the decreased cell viability of 
human malignant cells treated by microalgal extracts, particularly with the rapidly dividing 
ovarian carcinoma A2780 line. This cell line also seemed to be selectively targeted over the 
slowly dividing malignant cells, MCF7. Consequently, future studies should include evaluation 
of the effects of the microalgal extracts on rapidly dividing malignant cells. 
There is undoubtedly a great worldwide need for new molecules with antibacterial activity.  
Antimicrobial resistance kills 700,000 people per year and it has been estimated that these 
numbers will increase to 10 million deaths per year by 2050, if the trend does not change 
(O’Neill 2014). The results of the present study offer a new insight into the importance of 
unexplored microalgae from extreme environments as antibiotic producers. Although very 
promising results were obtained, significant further study is necessary before antibacterial 
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molecules from microalgae can undergo clinical investigation. The determination of the active 
molecules should, therefore, be the next step towards evaluating these extracts. This should then 
be followed by assessing the compounds with antibacterial resistant microorganisms, such as 
methicillin resistant S. aureus, followed by toxicity and bioavailability of the active compounds.   
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Table S1: Chemical analysis of water samples harbouring microalgae exhibiting (positive) 
and not exhibiting (negative) antibacterial activity. 
Water chemistry 
Standard
1
 
Fe Ni Cu Zn As Cd Pb pH 
0.3 0.025 0.002 0.03 0.005 0.00009 0.001 6.5-9 
Positive samples 
M23 21.5 0.673 0.803 2.53 0.002 0.001 0.008 2.9 
M2 8.680 0.144 0.040 42.40 0.002 0.675 0.050 2.9 
M9 1.317 <0.001 <0.001 0.006 0.0005 <0.001 <0.001 5.7 
M12 0.670 0.208 0.066 0.067 <0.001 <0.001 <0.001 6.9 
M18 0.363 0.001 0.001 0.003 <0.001 <0.001 <0.001 6.5 
M4 0.323 <0.001 0.002 0.010 0.001 <0.001 <0.001 6.0 
M40 0.231 0.002 0.006 <0.001 0.002 <0.001 <0.001 7.2 
M15 0.088 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 7.6 
M19 0.058 0.001 <0.001 0.001 <0.001 <0.001 <0.001 7.2 
M17 0.050 <0.001 <0.001 0.001 <0.001 <0.001 <0.001 7.1 
M6 0.045 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 8.0 
M13 0.043 0.001 <0.001 0.001 <0.001 <0.001 <0.001 6.9 
M16 0.040 <0.001 0.001 0.002 <0.001 <0.001 <0.001 7.0 
M21
 
0.029 <0.001 <0.001 0.003 <0.001 <0.001 <0.001 6.2 
M20 0.023 <0.001 0.001 0.001 <0.001 <0.001 <0.001 6.8 
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Table S1. Continued. 
Water chemistry 
Standard
1
 
Fe Ni Cu Zn As Cd Pb pH 
0.3 0.025 0.002 0.03 0.005 0.00009 0.001 6.5-9 
Negative  samples 
M38 4.58 0.257 0.671 16.9 0.002 0.070 1.76 4.4 
M8 1.014 0.001 0.001 0.005 0.0005 <0.001 <0.001 5.8 
M37 0.884 0.025 0.011 0.035 <0.001 <0.001 <0.001 7.4 
M36 0.612 0.016 0.020 0.012 0.008 <0.001 0.003 7.8 
M11 0.478 <0.001 <0.001 0.001 0.0004 <0.001 <0.001 6.6 
M10 0.349 <0.001 <0.001 0.002 0.0006 <0.001 <0.001 6.5 
M35 0.338 0.002 0.117 0.034 0.002 <0.001 <0.001 6.7 
M27 0.323 0.018 0.002 0.001 <0.001 <0.001 <0.001 7.6 
M14 0.289 0.005 0.001 0.001 <0.001 <0.001 <0.001 7.4 
M31 0.207 0.002 0.002 0.001 <0.001 <0.001 <0.001 5.7 
M5 0.166 <0.001 <0.001 0.005 <0.001 <0.001 <0.001 4.5 
M26 0.164 0.003 0.001 0.006 <0.001 <0.001 <0.001 5.3 
M24 0.155 0.006 0.012 0.009 0.002 0.018 <0.001 7.9 
M28 0.151 0.004 0.003 <0.001 <0.001 <0.001 <0.001 8.4 
M1 0.136 <0.001 <0.001 0.002 <0.001 <0.001 0.001 7.4 
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Table S1. Continued. 
1
Standard (ppm) is based on the Canadian water quality guidelines for protection of aquatic life 
(CCME, 2017). 
 
 
 
Water chemistry 
Standard
1
 
Fe Ni Cu Zn As Cd Pb pH 
0.3 0.025 0.002 0.03 0.005 0.00009 0.001 6.5-9 
Negative  samples 
M34 0.130 0.014 0.084 0.030 0.002 <0.001 <0.001 7.0 
M3 0.130 0.003 0.003 0.003 0.003 <0.001 <0.001 8.1 
M25 0.107 0.007 0.004 0.003 0.007 <0.001 <0.001 8.0 
M7 0.090 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 7.9 
M33 0.081 0.002 0.137 <0.001 <0.001 <0.001 <0.001 7.4 
M30 0.066 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 5.8 
M29 0.042 0.001 0.001 <0.001 <0.001 <0.001 <0.001 6.7 
M32 0.039 0.001 0.282 <0.001 <0.001 <0.001 <0.001 6.0 
M39 0.050 0.003 0.004 0.001 <0.001 <0.001 <0.001 6.9 
M22 0.001 0.010 0.042 0.007 0.200 <0.001 0.001 8.0 
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Table S2. Metabolites in promising microalgal extracts exhibiting antibacterial activity. 
Metabolite Microalgal Extracts 
Amino acids (M) M6  M9 M12 M15 M19 M20 M40 
Alanine 23.9 30.2 145 1060 1520 809 3 
Arginine 0.939 0.635 3.35 111 212 1.89 31.2 
Asparagine 45.2 12.3 5.03 525 682 16.2 12.5 
Aspartic acid 0.453 0.683 0.432 97.2 85.9 0.654 0.564 
Citruline 1.67 1.4 2.63 12.7 13.4 5.19 1.5 
Glutamine 3.32 2.77 23.4 67.8 131 9.34 11.7 
Glutamic acid 42.5 52.5 106 1210 1740 811 346 
Glycine 4.73 10.1 18.5 97.2 147 22.1 15.2 
Histidine 1.21 0.483 0.291 2.63 2.94 5.49 0.663 
Isoleucine 3.86 4.7 10.5 17.6 24.1 24.4 8.43 
Leucine 10.3 9.29 20.8 33.7 48.3 35.1 19.7 
Methionine 1.49 1.5 1.45 1.86 1.46 1.69 2.02 
Phenylalanine 2.15 2.63 5.25 15.3 21.3 7.1 4.36 
Proline 4.36 0.339 6.97 21.9 34.9 105 4.03 
Serine 7.47 16.6 31.9 473 751 53.1 48.1 
Threonine 5.59 7.86 16.3 47.7 65.1 31.6 22.2 
Tryptophan 0.149 0.411 1.08 6.75 8.79 5.66 0.855 
Tyrosine 0.974 1.34 6.92 14.4 22.2 7.92 2.66 
Valine 7.3 8.54 21.8 42 56.8 52.5 22.9 
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Table S2. Continued. 
 
 
Metabolite Microalgal Extracts 
Glycerophospholipids (M) M6  M9 M12 M15 M19 M20 M40 
LysoPhosphatidylcholine acyl 
C16:0 
11.7 15.1 47.4 4.92 17.3 0.124 0.129 
LysoPhosphatidylcholine acyl 
C18:2 
16.4 6.04 5.36 7.07 24.9 5.1 3.87 
Phosphatidylcholine diacyl C32:3 1.1 2.65 14.5 1.39 5.97 0.028 0.013 
Phosphatidylcholine diacyl C34:1 4.15 0.876 5.18 1.08 6.32 1.02 0.073 
Phosphatidylcholine diacyl C34:2 18.5 6.35 29 4.48 20 2.47 0.145 
Phosphatidylcholine diacyl C34:3 34.1 35 149 6.56 27.9 0.193 0.102 
Phosphatidylcholine diacyl C34:4 5.6 9.93 39.5 1.39 6.34 0.046 0.032 
Phosphatidylcholine diacyl C36:3 3.72 1.12 8.3 2.63 12.5 0.225 0.041 
Phosphatidylcholine diacyl C36:4 12.3 3.41 23.7 4.49 20.9 0.149 0.055 
Phosphatidylcholine diacyl C36:5 28.3 7.8 33.4 4.96 20.2 0.104 0.083 
Phosphatidylcholine diacyl C36:6 56.6 30.3 110 3.37 13.8 0.065 0.087 
Phosphatidylcholine diacyl C36:0 7.94 8.99 31.7 0.424 1.86 0.129 0.193 
Sphingolipids  (M)        
Hydroxysphingomyeline C22:2 0.043 0.022 0.121 0.136 0.514 0.02 0.014 
Hydroxysphingomyeline C16:1 0.039 0.015 0.052 0.012 0.046 0.019 0.024 
Sphingomyeline C20:2 0.069 0.032 0.247 0.041 0.014 0.006 0.008 
Sphingomyeline C24:0 0.324 0.15 0.172 0.178 0.203 0.606 0.137 
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Table S2. Continued. 
 
 
 
 
 
 
 
Metabolite Microalgal Extracts 
 Acylcarnitines (M) M6  M9 M12 M15 M19 M20 M40 
Decanoylcarnitine 0.17 0.146 0.044 0.072 0.076 0.078 0.199 
Decenoylcarnitine 0.238 0.277 0.195 0.261 0.226 0.293 0.312 
Biogenic amines (M)        
Alpha-aminoadipic acid 0.145 0.432 0.543 12.8 10.6 0.701 1.21 
Methioninesulfoxide 1.38 0.764 5.76 9.48 6.11 6.16 2.74 
cis-OH-pro 1.29 1.29 1.29 1.46 1.38 1.29 1.29 
Putrescine 0.364 0.969 0.976 0.0825 0.0145 0.123 0.0899 
Taurine 1.2 0.452 0.321 3.99 5.56 0.517 0.452 
